Smart Polymer Nanoparticles: Targeting Macrophages/Fibroblasts and Modulating the Microenvironment for Rheumatoid Arthritis Therapy Authors: Yao Wang, Meng Lin, Qi Sun, Tianfei Fan, Minglu Zhou, Wei Yang, Ting Zhang Published: 2026 ABSTRACT AbstractRheumatoid arthritis (RA) is a systemic autoimmune disease associated with a high disability rate. Its core pathogenesis involves immune dysregulation, characterized notably by the aberrant polarization of macrophages toward the pro-inflammatory M1 phenotype, along with the abnormal proliferation and invasion of fibroblast-like synoviocytes. These interrelated processes collectively contribute to progressive joint destruction. Although traditional drug therapies can alleviate symptoms, they are frequently accompanied by significant side effects and fail to achieve curative outcome. In this context, smart polymer nanoparticles (SPNs) have emerged as a promising platform for rheumatoid arthritis therapy, offering multifunctional capabilities. Here, we provide a comprehensive and timely analysis of the multifaceted therapeutic applications of SPNs in RA. By delivering immunomodulatory agents, smart polymer nanoparticles can rebalance macrophage polarization, promoting M1-to-M2 conversion. Moreover, they effectively suppress the pathological activation of fibroblasts, thereby inhibiting synovial proliferation and bone invasion. Furthermore, these nanoparticles can also disrupt the vicious cycle of disease progression by ameliorating metabolic dysregulation within the joint microenvironment. The challenges for the clinical translation of SPNs in RA therapy are discussed and the possible solutions are proposed. Collectively, SPNs fundamentally intervene in RA pathogenesis through precise targeting and intelligent drug release, enabling a highly effective and low-toxicity strategy. Introduction Rheumatoid arthritis (RA) is a chronic progressive autoimmune disease with a global prevalence of approximately 1%.1,2 The incidence rate among women is about 2 to 3 times higher than that among men, with the highest incidence occurring in individuals aged 40 to 60 years.3 Without effective treatment, approximately 50% of patients develop joint dysfunction within 2 to 3 years of onset, severely impairing daily living and work capabilities. RA patients commonly experience weight loss, low-grade fever, and morning stiffness, with the most distinctive feature being joint erosion. Arthritis typically initiates in the small joints (hands, wrists, and feet) and subsequently progresses to larger joints, including the elbows, shoulders, ankles, and knees. The course of the disease is unpredictable, ranging from days or weeks to months, and is highly recurrent. Most patients must live with it for life, enduring prolonged suffering. Persistent inflammation leads to synovial hyperplasia, fibrosis, and calcification, progressively damaging joint cartilage and bone.4–7 This ultimately causes joint space narrowing and fusion, resulting in various deformities such as swan neck deformity, buttonhole deformity, and ulnar deviation. These deformities severely impair joint function, sometimes leading to complete loss of mobility, significantly diminishing patients’ quality of life.8,9 The pathogenesis of RA is complex, with the immune system playing a central role.10–12 Macrophages, as key members of the immune system, play a critical role the progression of RA. Macrophages exhibit remarkable phenotypic plasticity and can differentiate into distinct functional phenotypes based on their environment and received signals, with M1 and M2 macrophages representing the two primary polarization states. M1 macrophages exert pro-inflammatory effects. When the body encounters pathogen invasion or an inflammatory environment, macrophages polarize toward the M1 phenotype. M1 macrophages secrete large amounts of pro-inflammatory cytokines such as tumor necrosis factor-α (TNF-α), interleukin-1 (IL-1), and interleukin-6 (IL-6). These cytokines further activate the immune system, recruiting more immune cells to the site of inflammation and triggering intense inflammatory responses that cause more severe damage to joint tissues. In contrast, M2 macrophages are anti-inflammatory and promote tissue repair. They secrete anti-inflammatory cytokines like interleukin-10 (IL-10), suppressing inflammatory responses and facilitating tissue repair and regeneration. In RA patients, the balance of macrophage polarization is disrupted, characterized by a significant increase in M1 macrophages and a relative decrease in M2 macrophages. This imbalance leads to persistently intensified inflammation that is difficult to control, as M1 macrophages function as the central effectors of synovial destruction. Upon polarization, M1 macrophages secrete a battery of pro-inflammatory cytokines—including TNF-α, IL-1β, IL-6, IL-12, and IL-23—that directly stimulate fibroblast-like synoviocytes to release additional inflammatory mediators and matrix metalloproteinases (MMPs), thereby initiating and amplifying synovial inflammation. Furthermore, M1 macrophages highly express MHC II molecules and co-stimulatory molecules (CD80 and CD86), conferring potent antigen-presenting capacity that activates naive T cells—particularly Th1 and Th17 subsets—thereby propagating T cell-dependent adaptive immune responses and establishing a broader inflammatory network. Simultaneously, M1-derived cytokines promote B-cell proliferation and differentiation into plasma cells that produce rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPAs); the resultant immune complexes further activate macrophages via Fc receptors and the complement system, driving them toward an even more pronounced M1 phenotype and creating a self-perpetuating inflammatory loop.13 Beyond immunological amplification, M1 macrophages are directly responsible for joint damage and bone erosion. They significantly upregulate receptor activator of nuclear factor-κB ligand (RANKL) while downregulating osteoprotegerin (OPG), thereby promoting osteoclast differentiation and bone resorption.14 In parallel, M1 macrophages release large quantities of ROS and nitric oxide (NO) via inducible nitric oxide synthase (iNOS), exacerbating oxidative stress and lipid peroxidation within the synovial microenvironment. The M1-derived inflammatory milieu also transiently upregulates NF-κB, ERK, and AKT signaling in osteoclast precursors, accelerating the expression of bone-resorptive genes such as cathepsin K, tartrate-resistant acid phosphatase (TRAP), and MMP-9, which collectively degrade cartilage matrix and subchondral bone.15 Collectively, these multifaceted pro-inflammatory and tissue-destructive functions establish M1 macrophages as the primary drivers of the chronic, self-amplifying pathology that characterizes RA. The prevailing M1/M2 macrophage polarization paradigm, while conceptually useful, has been substantially refined by single-cell RNA sequencing (scRNA-seq) analyses of rheumatoid synovium. Rather than a binary switch, synovial macrophages comprise a spectrum of transcriptionally distinct subpopulations—including Stat1⁺ pro-inflammatory cells, Fn1⁺ and Il7r⁺ regulatory subsets, C1q⁺ dual-phenotype cells, and Cd14⁺ hyperinflammatory monocytes—each exhibiting unique metabolic signatures and disease-associated trajectories.16 Li et al further resolved synovial tissue macrophages into MerTK⁺CD206⁺ homeostatic regulators and MerTK−CD206− inflammatory effectors, demonstrating that the relative abundance of these subsets, rather than a simplistic M1/M2 ratio, predicts treatment response and flare risk after therapy cessation.17 This heterogeneity is mirrored in the adaptive immune compartment: scRNA-seq of RA synovial fluid identifies clonally expanded CXCL13⁺ peripheral helper T cells that engage in prolific bidirectional communication with SPP1⁺/S100A12⁺ pathogenic macrophages, forming a synergistic triad with fibroblast-like synoviocytes to amplify IL-6 and MMP production.18 B cells, recruited and sustained by FLS-derived CXCL12, CXCL13, BAFF, and APRIL, contribute to ectopic lymphoid structure formation and autoantibody generation, while neutrophils release citrullinated autoantigen-laden NETs that perpetuate inflammation through TLR-9-mediated activation of both macrophages and FLS. Dendritic cells bridge innate and adaptive immunity by presenting citrullinated peptides to autoreactive T cells, further fueling the self-sustaining inflammatory loop.14 Collectively, these findings establish that RA is not driven by isolated macrophage dysregulation but by a dynamic, multicellular ecosystem in which macrophages, T cells, B cells, neutrophils, dendritic cells, and fibroblasts engage in reciprocal activation. The aberrant transformation of fibroblast-like synoviocytes (FLS) is also a crucial component in the pathogenesis of RA. For example, fibroblast activation protein-alpha (FAP-α), a surface biomarker that is virtually absent in normal adult FLS but present in rheumatoid arthritis patients, shows significant upregulation in pathological tissues.19 In RA, these cells exhibit abnormal proliferative capacity, continuously dividing and proliferating, leading to excessive growth and thickening of synovial tissue, forming vascular villi. These vascular villi progressively invade articular cartilage and bone tissue, releasing various matrix metalloproteinases (MMPs) and cytokines such as interleukin-15 (IL-15).20 MMPs degrade the extracellular matrix of articular cartilage and bone tissue, disrupting normal joint architecture.21 IL-15 activates T cells, stimulating them to secrete more pro-inflammatory cytokines, thereby intensifying the inflammatory response.22 This creates a vicious cycle that accelerates joint destruction. FLS extensively secrete complement C3 and activate it into the active form C3a. Macrophages highly express the specific receptor C3aR1 on their surface. Upon binding, C3a rapidly activates macrophages. Activated macrophages then massively secrete proinflammatory molecules like IFN-β. These signals in turn act on FLS, stimulating their excessive proliferation and increased secretion of IL-6 and MMP1, MMP3 (matrix metalloproteinases that degrade articular cartilage and bone matrix). Thus, the close interaction between macrophages and FLS significantly contributes to the progression of RA pathology.23 Through specific signaling axes, they form a stable positive feedback loop that continuously amplifies the inflammatory response and induces tissue damage, ultimately accelerating synovial hyperplasia and osteoclast differentiation. Beyond abnormalities in macrophages and fibroblast-like synovial cells, the joint microenvironment constitutes a complex ecosystem comprising multiple components such as extracellular matrix, cytokines, chemokines, and metabolic byproducts. In RA patients, massive inflammatory cell infiltration disrupts the cytokine network, leading to excessive release of proinflammatory cytokines and maintaining the microenvironment in a persistently hyperinflammatory state.24,25 Autoantibodies produced in RA patients—including anti-citrullinated peptide antibodies (ACPA) and rheumatoid factor (RF)—form immune complexes that activate the complement system.26–28 This activation further exacerbates inflammation via the complement-FcγR axis. Concurrently, the inflammatory response induces local metabolic disturbances within the synovial microenvironment, such as low pH, elevated reactive oxygen species (ROS) and glutathione (GSH) levels, hypoxia, and double-stranded DNA (dsDNA) accumulation.29 This entire process promotes osteoclast activation and proliferation while suppressing osteoblast activity, thereby creating an imbalance where bone resorption exceeds bone formation, ultimately leading to bone destruction and osteoporosis.30 Current treatment for RA primarily relies on traditional disease-modifying antirheumatic drugs (DMARDs), biologic DMARDs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs).31,32 Traditional DMARDs (such as methotrexate) inhibit dihydrofolate reductase, disrupting purine and pyrimidine synthesis to suppress immune cell proliferation and inflammatory responses.33 However, limitations exist, including a single mechanism of action and lack of targeting capability.34,35 Their systemic distribution results in insufficient drug concentrations at inflamed joints while increasing susceptibility to systemic toxicities.36 Common adverse effects include nausea, vomiting, oral ulcers, liver dysfunction, and bone marrow suppression, making treatment difficult for some patients. In contrast, biologic DMARDs exhibit higher specificity, such as tumor necrosis factor-α (TNF-α) antagonists and interleukin-6 (IL-6) antagonists. These biologics specifically target key cytokines in inflammatory pathways, precisely suppressing inflammatory responses and demonstrating significant efficacy in improving patient symptoms and controlling disease progression. Targeted synthetic DMARDs (tsDMARDs), a class of orally available small-molecule inhibitors that has fundamentally expanded treatment options. The primary representatives of tsDMARDs are the Janus kinase (JAK) inhibitors—tofacitinib, baricitinib, upadacitinib, and filgotinib—which function by competitively blocking ATP binding to JAK family members (JAK1, JAK2, JAK3, TYK2), thereby interrupting the JAK-STAT intracellular signaling cascade that transduces pro-inflammatory cytokine signals (eg, IL-6, IL-2, IFN-γ) and drives synovial inflammation and joint destruction.37 Unlike bDMARDs, which selectively neutralize individual extracellular cytokines via parenteral administration, tsDMARDs offer several clinically relevant advantages: oral bioavailability, rapid onset of action, short half-life facilitating washout, and the capacity to modulate multiple cytokine pathways simultaneously through intracellular blockade.38 Tofacitinib exhibits broader pan-JAK inhibition (JAK1/JAK3), whereas baricitinib targets JAK1/JAK2 with additional bone-protective effects; upadacitinib and filgotinib represent next-generation highly selective JAK1 inhibitors with improved efficacy and favorable hematologic safety profiles.39 Regulatory approvals position tsDMARDs alongside bDMARDs for moderate-to-severe RA following inadequate response or intolerance to csDMARDs, with real-world evidence demonstrating comparable or superior remission rates to TNF inhibitors in treat-to-target strategies. However, they also have drawbacks: Firstly, their high cost imposes a heavy financial burden on patients and families. Besides, the requirement for long-term injection administration presents challenges for treatment adherence and convenience. Moreover, there are also safety concerns, including an elevated risk of infections and potential allergic reactions.40 Beyond conventional anti-inflammatory and immunosuppressive strategies, emerging evidence supports the therapeutic potential of selectively inducing apoptosis in pathogenic synovial cells. Nanodelivery systems engineered to trigger apoptosis—via mitochondrial disruption, endoplasmic reticulum stress, or death receptor activation—offer a complementary paradigm that can simultaneously eliminate hyperplastic synoviocytes and inflammatory macrophages while minimizing systemic cytotoxicity.41 Traditional nanoparticles, such as liposomes and solid lipid nanoparticles, exhibit numerous advantages due to their unique nanoscale dimensions and specialized structures. As one of the earliest nanocarriers applied in drug delivery, liposomes possess excellent biocompatibility and targeting capabilities. Composed of phospholipids and other lipid materials forming a bilayer structure, they effectively encapsulate hydrophilic or hydrophobic drugs, delivering them to specific tissues or cells through passive or active targeting mechanisms. For instance, doxorubicin liposomes are widely used in clinical therapy. Compared to free doxorubicin, they reduce cardiac toxicity and enhance drug accumulation in tumor tissues, thereby improving therapeutic efficacy. Solid lipid nanoparticles, utilizing solid lipids as carrier materials, offer advantages such as high drug loading capacity, excellent stability, and controlled drug release. They significantly enhance drug bioavailability and reduce side effects. However, traditional nanoparticles also exhibit certain limitations in practical applications. Liposomes suffer from poor stability, prone to lipid oxidation and drug leakage during storage and circulation, which diminishes therapeutic efficacy. While solid lipid nanoparticles demonstrate improved stability, the potential retention of residual organic solvents from their preparation process poses potential hazards to human health.42,43 To overcome these limitations of traditional nanoparticles, smart polymer nanoparticles have emerged. The term “smart polymer nanoparticles” (SPNs) refers to intelligent macromolecular assemblies capable of undergoing reversible physicochemical or conformational transformations in response to subtle environmental variations, thereby enabling on-demand, spatiotemporally controlled therapeutic release. This “smartness” is operationalized through stimuli-responsive mechanisms that can be broadly classified into three categories: endogenous (internal), exogenous (external), and multi-stimuli-responsive systems. Endogenous stimuli originate from the pathological microenvironment itself and include pH gradients (acidic synovial fluid, pH 6.0–6.8), redox imbalances (elevated ROS and GSH), aberrant enzymatic activity (MMP-2/3/9/13 overexpression), hypoxia (HIF-1α stabilization), elevated extracellular ATP, and sustained pro-inflammatory cytokine surges (TNF-α, IL-1β, IL-6).44 Exogenous stimuli, by contrast, are applied from outside the body and encompass near-infrared light irradiation, alternating magnetic fields, ultrasound, and temperature changes, offering remote, noninvasive control over drug release kinetics.45 Multi-stimuli-responsive systems integrate two or more triggers—most commonly pH/ROS, MMP/GSH, or hypoxia/ROS dual combinations—to enhance release fidelity and minimize off-target activation in heterogeneous disease microenvironments where single cues may be ambiguous.46 In the context of RA, the inflammatory synovium presents a uniquely rich repertoire of endogenous triggers: the acidic, oxidative, protease-rich, hypoxic, and cytokine-dense milieu collectively provides a pathological “fingerprint” that SPNs can exploit for precision targeting. By engineering polymer backbones with stimulus-cleavable linkers (eg, acid-labile hydrazone, ROS-cleavable thioketal, GSH-reducible disulfide, MMP-cleavable peptide), conformation-switchable moieties (eg, pH-titratable amines), or phase-transition domains (eg, thermoresponsive PNIPAM), researchers can program nanoparticles to remain stable during systemic transit but disassemble, swell, or degrade specifically upon encountering the RA synovial microenvironment, thereby converting pathological signals into therapeutic actions.47 This conceptual framework is illustrated in Scheme 1. Prepared from synthetic or natural polymeric materials, these nanoparticles exhibit excellent biocompatibility, degradability, and plasticity. Compared to conventional nanoparticles, polymer nanoparticles offer broader material selection. Suitable polymer materials—such as polylactic acid (PLA), polylactic-poly(glycolic acid) copolymer (PLGA), chitosan, and polyvinyl alcohol—can be chosen based on drug properties and therapeutic requirements. By adjusting polymer structure and composition, precise control over nanoparticle performance is achievable. In drug loading and release, polymeric nanoparticles effectively encapsulate diverse drug types—including small molecules, proteins, and nucleic acids—and enable sustained, controlled, or targeted release by surface modifications. In recent years, smart polymeric nanoparticles demonstrate significant potential in treating rheumatoid arthritis. For instance, a 2024 study reported a polyarginine nanoparticle PEG-TK-NPArg, which effectively inhibits Toll-like receptor-9 (TLR9) activation. It significantly suppressed arthritic symptoms in a rat model of collagen-induced arthritis (CIA).48 Smart polymeric nanoparticles can precisely modulate macrophages, promoting their polarization from pro-inflammatory M1 to anti-inflammatory M2 phenotype, thereby effectively suppressing inflammatory responses.49,50 Besides, they can also specifically target FLS, inhibiting their abnormal proliferation and invasive capabilities, reducing synovial proliferation, and protecting articular cartilage and bone tissue from destruction.51,52 Moreover, by modulating cytokine networks within the joint microenvironment and improving metabolic dysregulation, these smart polymer nanoparticles provide robust support for restoring equilibrium in the joint microenvironment. As illustrated in Scheme 1, SPNs designed for RA therapy typically comprise a stimulus-responsive polymer core (eg, PLGA, chitosan, or PEGylated networks) encapsulating therapeutic payloads, decorated with targeting ligands (eg, folate, antibodies, or cell membranes) for active homing to inflamed synovium. Upon reaching the pathological joint microenvironment, the nanoparticles undergo stimulus-triggered structural transformations—such as acid-catalyzed hydrolysis, ROS-mediated bond cleavage, or enzyme-specific linker degradation—to release their cargo precisely at the site of inflammation, while minimizing systemic exposure. Scheme 1Schematic illustration of smart polymer nanoparticles (SPNs) for rheumatoid arthritis therapy. The system comprises a stimulus-responsive polymer core capable of responding to endogenous pathological cues present in the RA synovial microenvironment—including acidic pH, elevated reactive oxygen species (ROS), high glutathione (GSH), overexpressed matrix metalloproteinases (MMPs), hypoxia, and pro-inflammatory cytokines—as well as exogenous stimuli such as near-infrared (NIR) light or magnetic fields. Upon encountering these triggers, the polymer matrix undergoes conformational changes or chemical bond cleavage, resulting in controlled drug release at the inflammatory site. Active targeting ligands (eg, folate, antibodies, or biomimetic membranes) further enhance specific accumulation in inflamed joints.Diagram of rheumatoid arthritis microenvironment showing macrophage polarization, fibroblasts and joint structure.The diagram illustrates the rheumatoid arthritis microenvironment, focusing on macrophage polarization and fibroblast interaction. In the center, a joint structure is depicted, surrounded by macrophages and fibroblasts. Macrophages are shown transitioning between M1 and M2 states, influenced by interleukin 10 and transforming growth factor beta. Arrows indicate the movement and interaction between macrophages and fibroblasts. The outer circle displays various nanoparticles and cellular structures, representing the complex microenvironment. The diagram highlights the dynamic interactions within the rheumatoid arthritis affected area, emphasizing the role of cytokines and cellular components in disease progression. Schematic illustration of smart polymer nanoparticles (SPNs) for rheumatoid arthritis therapy. The system comprises a stimulus-responsive polymer core capable of responding to endogenous pathological cues present in the RA synovial microenvironment—including acidic pH, elevated reactive oxygen species (ROS), high glutathione (GSH), overexpressed matrix metalloproteinases (MMPs), hypoxia, and pro-inflammatory cytokines—as well as exogenous stimuli such as near-infrared (NIR) light or magnetic fields. Upon encountering these triggers, the polymer matrix undergoes conformational changes or chemical bond cleavage, resulting in controlled drug release at the inflammatory site. Active targeting ligands (eg, folate, antibodies, or biomimetic membranes) further enhance specific accumulation in inflamed joints. SPNs constitute a distinct subclass of organic nanocarriers defined by their capacity to undergo stimulus-triggered physicochemical transformations—such as bond cleavage, conformational switching, or phase transitions—that enable spatiotemporally controlled drug release.44 Within the broader taxonomy of nanomedicine platforms, SPNs occupy a strategic middle niche: unlike lipid-based carriers (liposomes, solid lipid nanoparticles) that offer established biocompatibility but limited structural tunability, or inorganic nanoparticles (gold, iron oxide, silica) that provide imaging/theranostic functionalities yet raise biopersistence concerns, polymeric systems combine versatile chemical design with defined biodegradation pathways.53 SPNs are further distinguished from passive polymeric nanoparticles by their programmed “intelligence”—the incorporation of stimulus-sensitive moieties (eg, acid-labile hydrazones, ROS-cleavable thioketals, GSH-reducible disulfides, enzyme-cleavable peptides) that confer responsiveness to endogenous pathological cues (pH, redox, enzymes, hypoxia, cytokines) or exogenous triggers (light, temperature, magnetic fields, ultrasound). This classification into endogenous, exogenous, and multi-stimuli-responsive systems positions SPNs as uniquely suited for chronic inflammatory diseases such as RA, where the pathological microenvironment itself provides a rich repertoire of activation signals.54 However, the translational trajectory of SPNs remains in its early stages: while liposomal formulations and PEGylated proteins have achieved clinical approval in oncology, no SPN has yet progressed beyond Phase 2 trials for RA, constrained by challenges in GMP-compliant scale-up, batch-to-batch reproducibility, sterilization without compromising particle integrity, and the need for long-term safety data regarding polymer degradation byproducts and immunogenicity. Nevertheless, the convergence of advanced polymer chemistry, microfluidic manufacturing, and AI-driven formulation optimization is progressively de-risking clinical translation, suggesting that SPNs—by virtue of their programmable responsiveness and synthetic versatility—represent one of the most promising next-generation platforms for precision rheumatology.55 Regulation of Macrophages Inhibiting Activation and Reprogramming of Macrophages In the pathogenesis of RA, dysregulated macrophage activation and phenotypic imbalance play central roles, wherein pro-inflammatory M1 macrophages are excessively activated and release large amounts of cytokines such as IL-1β, TNF-α, and IL-6 through key signaling pathways including NF-κB, MAPK, and JAK2/STAT3,56 exacerbating synovitis and joint damage, while anti-inflammatory M2 macrophages are functionally insufficient to counteract the inflammatory response. The NF-κB pathway acts as a core inflammatory regulator, where cytokines like TNF-α and IL-1β trigger IKK-mediated IκB degradation, leading to NF-κB nuclear translocation and transcription of pro-inflammatory genes; the MAPK pathway, particularly the p38 and JNK branches, promotes expression of IL-1β, TNF-α, and MMPs;57 and the JAK2/STAT3 pathway, activated by IL-6, facilitates STAT3 dimerization, nuclear translocation, and inflammation-related gene expression. Although inhibitors targeting the aforementioned pathways, such as JAK inhibitors, have been applied in clinical practice and offer therapeutic hope for some RA patients, challenges including high interpatient response heterogeneity and adverse reactions remain in clinical settings58 (Figure 1). Notably, novel delivery systems such as SPNs exhibit unique advantages: they not only precisely inhibit macrophage overactivation and the transmission of pro-inflammatory signaling pathways but also promote the transition of macrophages from the M1 phenotype to the M2 phenotype by upregulating anti-inflammatory factors such as IL-10 and arginase-1 (Arg-1), thereby restoring local immune balance in the joints. Figure 1Macrophage-related information and polarization subtypes. (a) The two sources of macrophages include prenatal embryonic tissue and postnatal bone marrow, which eventually develop into tissue-specific macrophages. (b) An overview of the multiple systemic diseases in which macrophages are involved, including neoplastic and non-neoplastic diseases. (c) Multiple environmental signals bind to receptors on macrophages and stimulate M0 macrophages to polarize into M1 or M2 phenotypes via modulating inflammatory signaling pathways, causing an imbalance between the M1 and M2 macrophage phenotypes that affects the release of inflammatory mediators, which are involved in the regulation of inflammatory and immune responses. Copyright (2025), reproduced with permission from BioMed Central.Macrophage origins, disease roles, M1/M2 phenotypes and inflammation pathways diagram.The diagram has three sections: macrophage origins, diseases and polarization. Macrophages originate prenatally from yolk sac and fetal liver and postnatally from bone marrow and blood, forming resident and monocyte-derived types. Diseases involving macrophages affect systems like nervous, circulatory, respiratory, digestive, urinary, endocrine, musculoskeletal and integumentary. Macrophage polarization involves M0 macrophages receiving signals, activating pathways such as NF-kappa B, MAPK, JAK-STAT, PI3K-AKT, inflammasome and cGAS-STING, leading to M1 or M2 phenotypes. M1 macrophages, linked to inflammation and reduced tumors, express CD86, CD80, MHCII and secrete iNOS, IL-6, IL-12, COX-2, TNF-alpha. M2 macrophages, linked to reduced inflammation and increased tumors, express CD163, CD206 and secrete IL-10, Arg-1, TGF-beta. Macrophage-related information and polarization subtypes. (a) The two sources of macrophages include prenatal embryonic tissue and postnatal bone marrow, which eventually develop into tissue-specific macrophages. (b) An overview of the multiple systemic diseases in which macrophages are involved, including neoplastic and non-neoplastic diseases. (c) Multiple environmental signals bind to receptors on macrophages and stimulate M0 macrophages to polarize into M1 or M2 phenotypes via modulating inflammatory signaling pathways, causing an imbalance between the M1 and M2 macrophage phenotypes that affects the release of inflammatory mediators, which are involved in the regulation of inflammatory and immune responses. Copyright (2025), reproduced with permission from BioMed Central. Xu et al59 developed an oxidized chondroitin sulfate - chitosan - sodium glycerol β - phosphate - Fn/siHMGB1 hydrogel system (OCF/siHMGB1). The self-healing and temperature-controlled gelation properties of the hydrogel ensure the stable release of siHMGB1. After entering macrophages, siHMGB1 targeted and downregulated the HMGB1/TLR4/NF-κB-p65 signaling pathway, promoting the polarization of pro-inflammatory M1 macrophages toward anti-inflammatory M2 macrophages. This not only effectively inhibited the release of pro-inflammatory cytokines such as IL-1β and TNF-α but also upregulated anti-inflammatory cytokines like IL-10. In animal experiments, it significantly alleviated RA symptoms and demonstrated a favorable safety profile and robust therapeutic efficacy. In another example, Chen et al60 prepared cBPM nanoparticles using the macrophage-targeting property of yeast β-glucan (Figure 2). These nanoparticles can be efficiently internalized by macrophages and release methotrexate (MTX) in a responsive manner. Briefly, methoxy polyethylene glycol (mPEG) was grafted onto the BYG chain via an esterification reaction between carboxylated mPEG (mPEG-COOH) and BYG, using 1,1′-carbonyldiimidazole (CDI) as a catalyst. This resulted in a water-soluble copolymer termed BYG-g-mPEG. The copolymer was then chemically crosslinked using 3,3′-dithiodipropionic acid (DTPA) to form the crosslinked product designated as cBP. Due to the hydrophobic nature of the sugar carbon rings and the hydrophilic grafted mPEG chains, cBP self-assembled into nanoparticles when dispersed in water. The water-insoluble drug MTX was subsequently loaded into these cBP nanoparticles, forming a drug-loaded system named cBPM. The cBPM nanoparticles were administered to mice with rheumatoid arthritis via tail vein injection. Owing to the specific recognition of β-glucans by the dectin-1 receptor on macrophages, cBPM was internalized by macrophages accumulated in the inflamed joint tissue. Experimental results indicated that the cBPM nanoparticles, decorated with β-glucan, are specifically internalized into macrophages via binding to the Dectin-1 receptor on the cell membrane. Within the high GSH intracellular environment, the disulfide bonds in the nanoparticle carrier break, leading to the controlled release of MTX. The released MTX inhibited dihydrofolate reductase, thereby affecting purine and pyrimidine synthesis, and significantly suppressing the phosphorylation and activation of both the ERK1/2 and p38 MAPK signaling pathways. Inhibition of these pathways reduced the nuclear translocation and transcriptional activity of key downstream transcription factors such as NF-κB and AP-1. This subsequently downregulated the expression of pro-inflammatory cytokines (eg, TNF-α, IL-1β, IL-6) and inflammatory mediators (eg, iNOS, COX-2). As a result, nitric oxide (NO) production was reduced, and macrophage polarization shifted from the pro-inflammatory M1 phenotype to the anti-inflammatory, tissue-repairing M2 phenotype. This study provided an effective natural polysaccharide-based nano-system for targeted RA therapy. Figure 2Preparation of BYG-based nanoparticle and its targeting therapy of rheumatoid arthritis. Constructed using Figures published in,56 Copyright (2022), reproduced with permission from Elsevier.BYG nanoparticles for arthritis: synthesis, injection, macrophage targeting.The diagram outlines the preparation and targeting of BYG-based nanoparticles for rheumatoid arthritis treatment. BYG is grafted with methoxy polyethylene glycol (mPEG) through esterification using CDI and DMSO, forming BYG-g-mPEG. This copolymer is crosslinked with DTPA to create cBP, which self-assembles into nanoparticles. Methotrexate (MTX) is loaded into these nanoparticles, forming cBPM. A mouse receives a tail vein injection of cBPM nanoparticles, targeting macrophages in inflamed joints. Nanoparticles are internalized via the Dectin-1 receptor, releasing MTX in response to high glutathione levels. MTX inhibits dihydrofolate reductase, affecting purine and pyrimidine synthesis and suppressing ERK1/2 and p38 MAPK pathways. This reduces NF-kappaB and AP-1 activity, downregulating pro-inflammatory cytokines like TNF-alpha, IL-1beta and IL-6 and shifts macrophage polarization from M1 to M2 phenotype. Preparation of BYG-based nanoparticle and its targeting therapy of rheumatoid arthritis. Constructed using Figures published in,56 Copyright (2022), reproduced with permission from Elsevier. Beyond employing nanoparticles for the delivery of chemotherapeutic agents, researchers have also investigated gene therapy as an alternative strategy to inhibit macrophage activation for RA treatment. For example, references61,62 both utilized amine-terminated polyamidoamine (PAMAM) dendrimers (ethylenediamine core, generation 5.0) as the base material and employed heptafluorobutyric anhydride as the fluorination reagent to modify the primary amines on the PAMAM surface via acylation. The two types of nanocomplexes (FP/miR-23b and FP/miR-30a) were assembled based on electrostatic interactions: the positively charged amino groups on FP attracted the negatively charged phosphate groups of the miRNA (plasmid or mimic), leading to the encapsulation of miRNA by FP and the formation of stable nanoparticles. After cellular uptake by macrophages, the FP/miR-23b nanocomplex specifically targeted and inhibited TAB2, TAB3, and IKKA, thereby blocking the NF-κB signaling pathway. This not only suppressed the secretion of inflammatory cytokines such as TNF-α and IL-1β but also induced apoptosis of M1-type macrophages. In contrast, FP/miR-30a targeted the Snai1 gene, reducing cytokine secretion through simultaneous inhibition of both NF-κB and MAPK signaling pathways. Both nano-systems significantly alleviated rheumatoid arthritis symptoms in animal models, offering innovative strategies for gene therapy in RA. Moreover, Yu et al63 synthesized a nanocomplex formed by the amphiphilic phosphorus dendrimer C17P10 and TNF-α siRNA. This nanocomplex possessed the ability to protect siRNA and promote macrophage internalization. In vitro, it significantly inhibited TNF-α expression in LPS-activated RAW264.7 cells. In the CIA model, it reduced the infiltration of inflammatory cells in joints and synovial hyperplasia, while decreasing the arthritis score and paw swelling degree. These results highlight the great potential of TNF-α gene silencing for RA treatment. Considering that the accumulation of dsDNA and activation of the STING pathway played a pivotal role in RA pathogenesis, Shen et al64 developed PEI-PDA@C-176 NPs, which can adsorb dsDNA and deliver the STING antagonist C-176 (Figure 3). In vitro, these nanoparticles effectively inhibited the activation of the STING pathway in macrophages and the secretion of inflammatory cytokines (eg, IFNβ, TNF-α, and IL-6). In vivo experiments confirmed that in multiple arthritis models, the nanoparticles alleviated joint damage by inhibiting the STING pathway, demonstrating good biocompatibility and therapeutic effects. Figure 3Illustration of (A) the Chemical Composition of PEI-PDA@C-176 NPs and (B) the mechanism utilized for therapeutic of RA via inhibiting the STING pathway. Copyright (2022), reproduced with permission from KeAi Communications Co.A diagram showing PEI-PDA@C-176 NPs for RA treatment via STING pathway inhibition.The diagram consists of two main parts labeled A and B. In part A, the chemical composition of PEI-PDA@C-176 nanoparticles is illustrated. It begins with PDA, which combines with C-176 to form PDA at C-176 and then with PEI to create PEI-PDA at C-176. An arrow points to a mouse labeled ′Rheumatoid arthritis′ with ′i.a. injection′ indicating intra-articular injection. Part B is divided into three sections. The left section shows the STING pathway, starting with dsDNA leading to cGAS, then cGAMP and STING, followed by TBK1 and IRF3, with C-176 inhibiting this pathway. The central section depicts an inflamed joint with a comparison between ′Model′ and ′Treated′ conditions. The right section illustrates NPs treatment, showing macrophages with reduced STING pathway activity and inflammatory cytokines and the adsorption of dsDNA with the release of C-176, leading to decreased inflammation and joint damage. Illustration of (A) the Chemical Composition of PEI-PDA@C-176 NPs and (B) the mechanism utilized for therapeutic of RA via inhibiting the STING pathway. Copyright (2022), reproduced with permission from KeAi Communications Co. Yang et al65 constructed R4F-NM@F127-Cel nanoparticles, which ingeniously combine the targeting advantage of neutrophil membranes with the cell-binding property of ApoA-I mimetic peptide (R4F). With a particle size of approximately 51.25 nm, these nanoparticles can target inflamed joints via adhesion molecules on neutrophil membranes and achieve precise cellular targeting by leveraging the binding between R4F and SR-B1 receptors on the macrophage surface. In vitro experiments confirmed that the nanoparticles inhibited M1 polarization of macrophages, promoted M2 transition, and reduced inflammatory cytokine release; in vivo experiments showed that in the CIA model, they significantly alleviated joint inflammation and bone erosion, decreased serum inflammatory cytokine levels, and exhibited lower hepatotoxicity than free celastrol (Cel). This study provides an innovative strategy integrating biomimetic targeting and immunomodulation for RA treatment. Similarly, to enhance the accumulation of drugs at RA lesion sites, Li66 developed a folate (FA)- and tumor necrosis factor-alpha aptamer (TNFα-Apt)-modified polydopamine (PDA)-coated manganese dioxide (MnO2) nanoplatform (MPMAF) for loading MTX in RA treatment. MPMAF achieved dual targeting through the binding of FA to folate receptors on macrophage surfaces and the specific binding of TNFα-Apt to TNFα, enabling extensive accumulation at RA lesion sites. MnO2 decomposed hydrogen peroxide to generate oxygen, alleviating hypoxia at inflammatory sites; the PDA shell scavenged reactive oxygen species (ROS), loaded MTX, and its photothermal effect provided adjuvant therapy. In the CIA model, MPMAF ameliorated joint inflammation and bone erosion via suppression of the NF-κB/NLRP3 pathway, which reduced pro-inflammatory cytokine levels and promoted macrophage M2 polarization. Beyond developing macrophage-targeted nano-delivery systems to improve drug enrichment in lesions, researchers have attempted to utilize nanoprobes capable of specifically identifying inflammatory macrophage phenotypes for drug screening. In this study, Mo et al67 constructed a macrophage phenotype-specific nanoprobe (MPSNPr), which achieves M1 macrophage-specific targeting through the binding of surface fluorophore H-aggregates to glucose transporter 1 (GLUT1) receptors. Using a high-throughput screening platform based on this nanoprobe, betulinic acid (BA) and salidroside (SAL) were identified as pro-inflammatory and anti-inflammatory candidate drugs, respectively. Subsequently, polysaccharide nano-adjuvants (Dex-BA and Dex-SAL) were developed. Among them, Dex-SAL promoted the polarization of macrophages toward the anti-inflammatory M2 phenotype and alleviated joint inflammation and cartilage destruction in the CIA model. This strategy utilized polysaccharide nano-adjuvants to reprogram macrophage, offering a new method for RA immunotherapy. Weng et al68 developed ALG@SrR-MoS2 NFs-Ppy NPs, a phototherapeutic glycan-integrated nanogel complex that combines photothermal/photoelectric responsive functions with drug delivery properties. This hydrogel has high mechanical strength and enables transdermal delivery of strontium ranelate (SrR). Under near-infrared (NIR) light irradiation, it generates photothermal and photoelectric effects to enhance drug penetration, activate heat shock proteins (HSPs), and thereby induce the polarization of macrophages toward the M2 phenotype. In the zymosan-induced RA model, the complex significantly alleviated joint inflammation, reduced the release of ROS and pro-inflammatory cytokines, and effectively improved joint structure, providing a new approach for the local treatment of RA. Sinomenine (Sin), an alkaloid extracted from sinomenium acutum, has been reported to suppresses macrophage-derived pro-inflammatory cytokines. Despite its proven clinical efficacy, its use remains limited due to poor aqueous solubility and inadequate targeting capability. In light of this, researchers proposed a “drug-in-therapeutic polymer” strategy and constructed PAM-HA@Sin nanoparticles to improve the solubility and targeting efficiency of Sin.69 The hyaluronic acid (HA) derivative PAM-HA, modified with aminated PEG, alendronate (Ald), and methionine (Met), not only possesses bone-adhesive ability and long joint retention but also scavenges ROS. In a ROS-rich environment, PAM-HA@Sin nanoparticles disintegrate and release Sin. By inhibiting the NF-κB pathway, Sin downregulates pro-inflammatory cytokines and upregulates anti-inflammatory cytokines, while the HA backbone exerts a joint lubrication effect. In the CIA model, compared with free Sin injections, these nanoparticles significantly prolonged joint retention time, alleviated joint swelling and cartilage destruction, and achieved synergistic antioxidant and anti-inflammatory therapy. To achieve the targeted delivery and on-demand release of multiple drugs, a dual-sensitive chondroitin sulfate (CS)-based nanocarrier was fabricated for the co-delivery of glucosamine (GlcN) and tofacitinib (Tof).70 In the acidic environment of the joint cavity, GlcN is first cleaved from the CS polymer to repair cartilage damage; subsequently, CS is internalized by macrophages via binding to CD44, and intracellular ROS triggered micelle disintegration to rapidly release Tof/GlcN. The combined effects of tofacitinib, glucosamine, and ROS consumption effectively promoted M1-to-M2 polarization and alleviate inflammation. Both in vitro and in vivo experiments confirmed the significant synergistic therapeutic effect of this nanoplatform for RA, providing a new method integrating cartilage repair and inflammatory regulation. Zhu et al71 designed FA-TP@VA NPs nanomicelles leverage the synergy between pegylated retinoic acid and triptolide (TP). FA-TP@VA NPs (TP concentration: 10 ng/mL) significantly reduced the secretion of IL-1β, IL-6, and TNF-α in LPS-activated RAW 264.7 cells, with inhibition rates of 58%, 42%, and 60%, respectively. This effect was superior to that of free TP (inhibition rates: 30%–45%). Furthermore, FA-TP@VA NPs downregulated the expression of key osteoclast-related genes (NFATc1, c-Fos, MMP-9). Specifically, the mRNA level of NFATc1 was decreased by 65% compared with the model group, thereby indirectly mitigating joint bone erosion in RA. Induction of Macrophage Apoptosis or Ferroptosis In the pathological progression of RA, hyperactivated M1 macrophages continuously release large amounts of inflammatory cytokines. This not only directly induces synovial cell proliferation and exacerbates local inflammatory infiltration but also accelerates cartilage erosion and bone destruction through pathways such as osteoclast activation, severely impairing patients’ joint function and quality of life. Therefore, precisely targeting and eliminating abnormally activated M1 macrophages to disrupt the inflammatory cycle at its source has become a central focus in RA therapy. The research team led by Pan conducted an in-depth analysis of synovial tissue from 32 RA patients and 15 healthy controls. Results revealed that iron ion concentrations in synovial tissue from RA patients were significantly elevated by 2.3-fold compared to controls (P<0.01). The proportion of cells positive for the lipid peroxidation marker 4-HNE reached 68% and these areas of iron metabolism abnormalities showed high colocalization with CD68-positive macrophages, confirming the pathological role of macrophages as key target cells for ferroptosis in joint lesions. To further validate the mechanism in vivo, they established a CIA mouse model and injected the ferroptosis inhibitor Liproxstatin-1 (LPX-1, 5 mg/kg) via vein injection, and the results showed that LPX-1 intervention significantly downregulated the expression levels of pro-inflammatory factors such as IL-6 and TNF-α in synovial tissue while upregulating the expression of the anti-apoptotic protein Bcl-2. Moreover, it blocked the lipid peroxidation chain reaction by inhibiting the degradation of GPX4, a core regulator of ferroptosis.72 This finding strongly confirms the dependence of its efficacy on the regulation of macrophage ferroptosis. Therefore, specific approaches such as targeted drug delivery, photothermal effect-mediated induction, or gene silencing to induce apoptosis or ferroptosis in these pro-inflammatory macrophages, thereby directly eliminating the source of inflammation, are considered highly effective strategies for blocking the pathological progression of RA. This also offers novel insights for addressing the side effects associated with systemic anti-inflammatory treatments in conventional therapy. In recent years, breakthroughs in research on SPNs have provided novel approaches and methodologies for RA treatment in this field. For example, Kumar et al73 prepared folate-conjugated glycol-chitosan nanoparticles (MFGCN), which ingeniously utilize the targeting property of folate receptor β to achieve precise localization of activated macrophages. With a particle size of approximately 300 nm, these nanoparticles can release MTX in a pH-responsive manner under the acidic inflammatory microenvironment. In vitro experiments showed that MFGCN induces mitochondrial membrane potential disruption, production of ROS and reactive nitrogen species (RNS) in macrophages, thereby promoting cell apoptosis. The induction of apoptosis is typically associated with increased ROS levels.74 In the adjuvant-induced arthritis (AIA) model, MFGCN effectively reduced serum levels of pro-inflammatory cytokines (TNF-α, IL-1β), enhanced antioxidant capacity, and significantly improved joint structural damage by targeting inflamed joint sites, demonstrating favorable therapeutic effects of combined targeted delivery and microenvironment modulation. The suboptimal efficacy of monotherapy underscores the necessity of combination drug therapy for managing and treating RA. Therefore, researcheres75 adopted an innovative dual-drug co-delivery strategy by preparing MTX-loaded lipid-polymer hybrid nanoparticles (MTX-LPHNPs) and aceclofenac (ACE)-loaded nanostructured lipid carriers (ACE-NLCs). ACE-NLCs exhibited efficient transdermal penetration ability, while MTX-LPHNPs regulated RA inflammation and immune responses via systemic administration. In vitro experiments revealed that the combined use of these two formulations not only inhibited the secretion of inflammatory cytokines by LPS-stimulated THP-1 macrophages but also induced cell apoptosis and inhibited autophagy through CD40-mediated signaling and Akt1 regulation. In the RA rat model, dual-drug co-delivery therapy successfully restored paw bone and joint structures, with efficacy comparable to that of commercial formulations, confirming the great potential of dual-drug nano-co-delivery as a combined therapeutic regimen for RA. MTX Eliminating pro-inflammatory M1 macrophages is a promising strategy for RA treatment. In light of this,76 polypyrrole-iron phosphate-methotrexate nanoparticles (PPy-FePi-MTX NPs) were designed to synergistically eliminate pro-inflammatory macrophages through multiple mechanisms. These nanoparticles could release active components in response to the inflammatory microenvironment: MTX directly induced apoptosis of M1 macrophages; under near-infrared (NIR) laser irradiation, polypyrrole generates a photothermal effect to further promote cell apoptosis. Meanwhile, intracellular Fe3⁺ was reduced to Fe2⁺ by GSH. The resultant Fe2⁺ then catalyzed the Fenton reaction, converting H2O2 into highly toxic hydroxyl radicals, ultimately triggering ferroptosis. Concurrently, PO43− enhanced the anti-RA efficacy by disrupting lysosomal pH homeostasis to inhibit autophagy. In the CIA model, PPy-FePi-MTX NPs significantly reduced joint swelling, inflammatory cytokine levels, and bone erosion, fully verifying their therapeutic potential in eliminating pro-inflammatory macrophages through multi-mechanism synergy. Finally, the design of nanocarrier-based depot system has been a promising strategy for achieving sustained therapeutic efficacy. Yang et al77 developed an injectable bioadhesive hyaluronic acid hydrogel (Gel) loaded with folate-functionalized polydopamine nanoparticles (FA-PDA@Leon), innovatively constructing a local drug depot (Figure 4). The Gel exhibits in situ gelation and strong adhesive properties, enabling tight adherence to joint tissues and significantly prolonging the retention time of nanoparticles at inflammatory sites. FA-PDA@Leon, leveraging the targeting effect of folate, acts precisely on macrophages. In vitro, this system effectively inhibits the JAK2/STAT3 inflammatory signaling pathway in macrophages, reduces pro-inflammatory cytokine release, and protects chondrocytes by regulating ferroptosis/ferritinophagy. Animal experiments showed that in the CIA model, it significantly alleviated joint swelling, reduced inflammation scores, and promoted joint function recovery without obvious systemic toxicity, providing a new effective strategy for long-term RA treatment. Figure 4Schematic diagram of the medicine-loaded nanoparticle-encapsulated hydrogel for RA treatment. (A) Illustration of the preparation of the FA-PDA@Leon nanoparticles and the Gel/FA-PDA@Leon hydrogel. (B) The Gel/FA-PDA@Leon hydrogel is injected intra-articularly into the ankle joint, which is then in situ gelled in the cavity. (C) The in situ formed hydrogel is tightly bonded with surrounding tissues and serves as a depot of nanoparticles for prolonging their retention. (D) The released nanoparticles can target and enter into the M1 macrophage for targeted delivery of Leon. (E) The hydrogel reverses the M1 polarization of macrophage to suppress inflammatory response. (F) The hydrogel protects chondrocytes from ferroptosis. Copyright (2024), reproduced with permission from Elsevier.Nanoparticle hydrogel for RA: prep, inject, impact on macrophages & chondrocytes.The schematic diagram illustrates the medicine-loaded nanoparticle-encapsulated hydrogel for RA treatment. Image A shows the preparation process: PDA undergoes surface modification to become FA-PDA, which is then loaded with medicine to form FA-PDA@Leon and finally encapsulated in hydrogel as Gel/FA-PDA@Leon. Image B depicts intra-articular injection into a rat′s ankle joint, showing in situ gelation in RA-affected areas. Image C highlights the local depot of nanomedicines, with Gel/FA-PDA@Leon hydrogel interacting with biological tissues. Image D focuses on targeted delivery to M1 macrophages. Image E demonstrates anti-inflammation effects, showing M1 macrophage conversion to M0 macrophage. Image F illustrates chondroprotection, highlighting chondrocyte protection from ferroptosis. The diagram emphasizes the hydrogel′s role in targeted delivery and inflammation suppression. Schematic diagram of the medicine-loaded nanoparticle-encapsulated hydrogel for RA treatment. (A) Illustration of the preparation of the FA-PDA@Leon nanoparticles and the Gel/FA-PDA@Leon hydrogel. (B) The Gel/FA-PDA@Leon hydrogel is injected intra-articularly into the ankle joint, which is then in situ gelled in the cavity. (C) The in situ formed hydrogel is tightly bonded with surrounding tissues and serves as a depot of nanoparticles for prolonging their retention. (D) The released nanoparticles can target and enter into the M1 macrophage for targeted delivery of Leon. (E) The hydrogel reverses the M1 polarization of macrophage to suppress inflammatory response. (F) The hydrogel protects chondrocytes from ferroptosis. Copyright (2024), reproduced with permission from Elsevier. The macrophage-targeting strategies reviewed herein exploit distinct receptor systems with differential expression patterns, endocytic mechanisms, and immunological consequences. Folate receptor-β (FR-β) is highly upregulated on activated M1 macrophages in RA synovium; folate-modified nanoparticles (eg, MFGCN, FA-LEF-NPs, MPMAF) achieve targeting via clathrin-mediated endocytosis with the advantages of low ligand cost and established chemistry, yet pre-existing anti-folate antibodies and FR-β expression on non-macrophage populations may compromise specificity.78 β-Glucan targets Dectin-1, a C-type lectin receptor expressed on macrophages and dendritic cells; beyond mere delivery, Dectin-1 engagement activates the Syk-CARD9-NF-κB signaling axis, directly promoting M1-to-M2 repolarization and ROS suppression, conferring dual targeting and immunomodulatory functions.79 CD44, a hyaluronan receptor overexpressed on activated macrophages, enables HA-coated nanoparticles to undergo CD44-mediated endocytosis. HA itself possesses intrinsic anti-inflammatory and ROS-scavenging properties, but CD44 is also abundant on synovial fibroblasts and T cells, reducing macrophage exclusivity.80 SR-B1, a scavenger receptor enriched on M1 macrophages, recognizes anionic phospholipids presented on macrophage membrane coatings, offering high inflammatory specificity.81 Neutrophil membrane-coated nanoparticles leverage a multi-ligand approach—LFA-1 binds ICAM-1, CXCR2 follows IL-8 gradients, and CD11a/CD18 mediates transendothelial migration—achieving superior inflammatory homing efficiency, though isolation complexity and batch heterogeneity limit scalability.82 In summary, while FR-β and CD44 ligands offer synthetic accessibility, Dectin-1 and SR-B1 provide higher macrophage specificity and functional immunomodulation, whereas biomimetic membranes achieve the most robust inflammatory targeting at the cost of manufacturing reproducibility. Regulation of Fibroblasts (FLSs) Activated synovial FLSs secrete large quantities of proteolytic enzymes, such as matrix metalloproteinases and cathepsins. These enzymes directly degrade collagen and proteoglycans, which are essential components of articular cartilage and bone, leading to joint structural damage. The sustained production of cytokines, including IL-6, IL-8, GM-CSF, and PGE2, maintains the activation of macrophages and lymphocytes, forming a positive feedback loop that exacerbates the synovial hypoxia–inflammation vicious cycle. Furthermore, FLSs highly express RANKL and downregulate osteoprotegerin (OPG), thereby promoting osteoclast differentiation and contributing to bone erosion. Qi et al constructed fibroblast activation protein (FAP)-targeted zinc ferrite nanoparticles (FAP-ZF-NPs) to achieve precise treatment of RA through a synergistic mechanism involving “FAP-targeted delivery – endoplasmic reticulum stress (ERS) activation – mitochondrial dysfunction,” combined with the magnetothermal effect of an alternating magnetic field (AMF) to enhance therapeutic efficacy.83 Among these, zinc ferrite nanoparticles (ZF-NPs) serve as the core carrier, exhibiting excellent magnetothermal conversion capability (enabling local temperature elevation to 42°C under AMF exposure) while directly inducing endoplasmic reticulum stress and mitochondrial dysfunction in FLSs. By leveraging the binding of FAP peptides to FAP, which is highly expressed on RA-FLSs, the enrichment efficiency of the nanoparticles in the inflamed synovium was increased by 3.2-fold, thereby improving targeting specificity. Concurrent activation of the ERS and mitochondrial dysfunction pathways, together with AMF-triggered localized heating, not only enhances ERS and mitochondrial dysfunction but also enables “on-demand therapy,” reducing toxicity in non-target tissues. Both in vitro and in vivo experiments confirmed that FAP-ZF-NPs, with the assistance of AMF, can efficiently eliminate FAP⁺ FLSs, suppress synovial inflammation and bone erosion, and exhibit a favorable safety profile, thereby offering a new direction for the clinical treatment of RA. To address the core pathological feature of aberrantly enhanced glucose metabolism in FLS RA, a HAP-1 peptide-modified dual prodrug nanodelivery system (Figure 5), HAP−1NPDC+LND was constructed.84 The released diclofenac (DC) from the nanoparticles specifically bound to glucose transporter 1 (GLUT-1) on the FLS surface, inhibiting GLUT-1-mediated transmembrane glucose transport. Lonidamine (LND) targeted and inhibited hexokinase 2 (HK-2), a rate-limiting enzyme in the glycolytic pathway. Notably, individual suppression of either GLUT-1 or HK-2 induced a compensatory upregulation of the other targets in FLS (eg, increased GLUT-1 expression following HK-2 inhibition). In contrast, the synergistic action of DC and LND (at an optimal 2:1 ratio) simultaneously downregulated both GLUT-1 and HK-2, thereby preventing FLS from maintaining metabolic activity via compensation and ultimately suppressing their survival, proliferation, and activation. Immunohistochemistry revealed reductions of 72% and 68% in GLUT-1 and HK-2 expression, respectively, in synovial tissue, along with a 65% decrease in M1 macrophage (CD86⁺) infiltration and a 70% reduction in activated FLS (FAP-α⁺). Both in vitro and in vivo experiments confirmed that HAP−1NPDC+LND effectively modulated FLS metabolism, suppresses synovial inflammation, and protected bone and cartilage structures. Figure 5Schematic illustration of synergistic metabolic modulation of FLS with targeted dual prodrug nanoparticles (HAP−1NPDC+LND) to mitigate RA. (A) Schematic design of the HAP-1 peptide-modified polymeric dual prodrug nanoparticles (HAP−1NPDC+LND); (B) Upon i.v. injection, HAP−1NPDC+LND would target the FLS in inflamed joints, triggering the release of DC and LND in response to the high GSH microenvironment within FLS. The released DC blocks glucose uptake, while LND inhibits glycolytic enzymes, thereby synergistically suppressing the survival, proliferation and activation of FLS. In addition, targeted metabolic regulation of FLS can reduce the secretion of pro-inflammatory factors and lactic acid, thereby mitigating macrophage activation and regulating SME. Copyright (2025), reproduced with permission from Elsevier.Diagram of dual prodrug nanoparticles targeting FLS in a CIA mouse model.A diagram illustrating the co-assembly of HA-SS-DC and HA-SS-LND into NP subscript DC plus LND, further modified with HAP-1 peptide for FLS targeting. In the CIA mouse model, the nanoparticles target FLS, releasing DC and LND in response to GSH. DC inhibits GLUT-1, causing glucose deprivation, while LND inhibits HK-2, reducing glycolytic activity. This leads to decreased ATP, pyruvic acid and lactic acid production, suppressing FLS survival, proliferation and activation. The macrophage section shows LPS binding to TLR4, activating NF-kB p65 and increasing pro-inflammatory factors, contributing to a pro-inflammatory reaction. The diagram includes labels for survival, proliferation, activation and pro-inflammatory reaction, with symbols for DC, LND, HA and HAP-1 peptide. Schematic illustration of synergistic metabolic modulation of FLS with targeted dual prodrug nanoparticles (HAP−1NPDC+LND) to mitigate RA. (A) Schematic design of the HAP-1 peptide-modified polymeric dual prodrug nanoparticles (HAP−1NPDC+LND); (B) Upon i.v. injection, HAP−1NPDC+LND would target the FLS in inflamed joints, triggering the release of DC and LND in response to the high GSH microenvironment within FLS. The released DC blocks glucose uptake, while LND inhibits glycolytic enzymes, thereby synergistically suppressing the survival, proliferation and activation of FLS. In addition, targeted metabolic regulation of FLS can reduce the secretion of pro-inflammatory factors and lactic acid, thereby mitigating macrophage activation and regulating SME. Copyright (2025), reproduced with permission from Elsevier. Ma et al addressed the low bioavailability and significant gastrointestinal side effects of oral irinotecan (IGUR) formulations by developing an in situ-forming injectable hydrogel delivery system loaded with nano-irinotecan (NanoIGUR).85 Polyvinyl alcohol (PVA) served as the dispersant and stabilizer, while bis-mercapto polyethylene glycol (HS-PEG-SH) acted as the crosslinking agent. The hydrogel’s three-dimensional network structure restricted NanoIGUR diffusion, enabling sustained drug release. Experimental results demonstrated that the NanoIGUR-loaded hydrogel dose-dependently inhibited proliferation of rheumatoid arthritis-derived fibroblast-like synovial cells (RA-FLS). Concurrently, RA-FLS migration rate decreased to 22.42% and invasion rate to 20.74%, both significantly lower than the free drug group (migration rate 44.69%, invasion rate 44.59%), confirming its association with suppressed matrix metalloproteinase (MMP) expression. In summary, the NanoIGUR-loaded hydrogel employs a synergistic “nano-solubilization - gel-controlled release - subcutaneous administration” approach. This approach ensures therapeutic efficacy for RA while addressing the limitations of oral elamodol, including low bioavailability, pronounced side effects, and frequent dosing requirements. While macrophage-directed strategies dominate the current RA nanomedicine landscape, synovial FLS represent an equally critical therapeutic node, and their targeting warrants commensurate attention. Fibroblast activation protein-α (FAP) is markedly upregulated on activated FLS in the RA synovium; FAP-targeted zinc ferrite nanoparticles (FAP-ZF-NPs) have demonstrated therapeutic efficacy by inducing endoplasmic reticulum stress and mitochondrial damage in pathogenic FLS,83 and FAPI-based PET/CT imaging is increasingly validated for assessing RA disease activity and treatment response. Cadherin-11 (CDH11), a cell–cell adhesion molecule enriched in rheumatoid synovium, mediates fibroblast contacts and synovial hyperplasia. Integrin-targeting strategies, particularly RGD peptide-modified nanoparticles directed against αvβ3 or α5 integrins, not only deliver anti-angiogenic payloads but also competitively inhibit FLS–endothelial interactions and suppress neovascularization in inflamed joints.86 Emerging FLS-specific ligands—including CD44, CD248 (endosialin), podoplanin (PDPN), and THY1 (CD90)—offer further opportunities for subset-specific targeting, as single-cell atlases have revealed that distinct FLS subpopulations (eg, ITGA5+ sublining fibroblasts) differentially drive inflammation versus tissue destruction.87 Collectively, these FLS-directed approaches complement macrophage-centric strategies by addressing the stromal engine of synovial invasion and pannus formation. Remodeling the Macrophage-Synovial Fibroblasts Crosstalk Remodeling the crosstalk between macrophages and synovial fibroblasts represents a crucial approach for treating RA using intelligent polymeric nanoparticles. Its core mechanism lies in blocking the inflammatory positive feedback loop between macrophages and synovial fibroblasts, thereby effectively inhibiting synovial hyperplasia and bone erosion—providing novel ideas and methods for RA therapy.88 Relevant studies have provided strong evidence to support this strategy. Inspired by synovial lipid-hyaluronic acid complexes, Wang et al developed a hyaluronic acid-polycaprolactone copolymer/nanoparticle hydrogel (HP@CEL), which enabled the local release of celastrol (CEL).89 HP@CEL mimicked the structure of natural synovial lipid-HA complexes; CEL inhibited M1 macrophage polarization and synovial fibroblast proliferation by inhibiting the TLR4/NF-κB pathway, successfully blocking the inflammatory positive feedback loop between these two cell types. In the CIA mouse model, HP@CEL significantly alleviated joint inflammation and bone erosion, promoted cartilage matrix repair, and exhibited excellent biocompatibility. This study provided a biomimetic therapeutic strategy for regulating the abnormal crosstalk between macrophages and synovial fibroblasts in RA. To address the core issues of metabolic dysregulation in synovial cells (macrophages and fibroblast-like synoviocytes, FLSs) and the poor targeting efficiency of conventional gene therapy in RA, Zhang et al constructed a near-infrared (NIR)-responsive gene delivery system (APPC/pHO-1).90 The system is composed of four modular components to achieve synergistic functions: a gold nanorods (AR) that converts 808 nm NIR to thermal energy to activate HSP70 promoter; a chitosan-modified polyethyleneimine (CS-PEI) that enabled CD44-targeted gene delivery and enhanced endosomal escape through the proton sponge effect; a polystyrene sulfonate (PSS) interlayer for stabilizing the AR core and CS-PEI coating; and an HSP70-driven HO-1 plasmid (pHO-1) that upregulated heme oxygenase-1 expression to suppress glycolysis and induce anti-inflammatory polarization. Cellular experiments demonstrated that treatment with APPC/pHO-1 plus NIR irradiation reduced the levels of pro-inflammatory cytokines (TNF-α, IL-6) by 60% in macrophage supernatants, downregulated GLUT1 and HK2 expression in FLSs by 45%, and decreased MMP9 secretion by 58%. Moreover, supernatants from HO-1-overexpressing FLSs reduced iNOS expression in macrophages by 52% and increased CD206 expression by 2.8-fold, thereby blocking cross-cellular inflammatory signaling. By simultaneously modulating both macrophages and FLSs, the nanoparticle system disrupted intercellular inflammatory communication and achieved a 40% greater therapeutic efficacy compared to strategies targeting only one cell type. To target the core pathological features of RA—“oxidative stress imbalance - macrophage M1 polarization - dysfunction of FLSs”—researchers have designed and synthesized metformin-derived carbon dots (MCDs).91 The nanoparticle surface is rich in electron-donating groups such as -OH, -NH2, and C=O and features a 15.90% nitrogen doping, presenting as pyrrole nitrogen, graphitic nitrogen, and amino nitrogen. MCDs significantly reduce ROS levels in LPS+IFN-γ-stimulated macrophages and FLSs through enzyme-like catalytic activity and electron transfer from surface functional groups. They enhance intracellular superoxide dismutase (SOD) and catalase (CAT) activity, mitigate oxidative stress damage, and demonstrate markedly superior efficacy compared to bulk metformin. By scavenging ROS, MCDs inhibit NLRP3 inflammasome activation, downregulate M1 cytokine (TNF-α, IL-6) secretion, and upregulate M2 cytokine (IL-4, IL-10) expression, promoting macrophage polarization from M1 to M2 in both normal and inflammatory conditions. It downregulates mRNA and protein expression of α-SMA, Col-I (fibrosis markers), and TNF-α, IL-6 (inflammatory factors) in inflamed FLSs, significantly reducing FLS viability under inflammatory conditions and promoting apoptosis. In vivo and in vitro experiments confirm that MCDs, through the synergistic mechanism of “ROS scavenging - macrophage polarization - FLS homeostasis restoration,” effectively alleviate RA joint inflammation, protect osteochondral structures, and inhibit synovial fibrosis. In summary, through the design of diverse intelligent polymeric nanoparticles, these studies remodel the macrophage-synovial cell crosstalk from multiple aspects—including blocking inflammatory positive feedback loops and reprogramming macrophage function—all exhibiting favorable efficacy in RA treatment and providing diversified and effective strategies for managing this disease. Microenvironment Modulation The inflammatory lesions in RA represent more than just sites of inflammatory cell accumulation; they are defined by a highly specific local microenvironment that represent pathological manifestations of disease progression. Due to excessive proliferation of synovial cells, dense infiltration of inflammatory cells, and heightened metabolic activity, these lesions generate substantial acidic metabolic byproducts (eg, lactic acid), leading to a marked reduction in local pH (6.0–6.8), significantly lower than that in the normal tissues of 7.2–7.4. Second, over-activated M1 macrophages, neutrophils, and other cells release large amounts of ROS through respiratory bursts. Concurrently, GSH levels within the lesion abnormally increase, exacerbating lipid peroxidation and cellular damage. Beyond these redox and acid-base imbalances, the RA microenvironment is further characterized by several additional pathological hallmarks that can be exploited as therapeutic triggers. Third, the invasive synovial pannus and hyperplastic tissue create profound local hypoxia, with oxygen tensions frequently falling below 1–2% (compared to ~5–7% in normal synovium), which stabilizes hypoxia-inducible factors (HIF-1α/2α) and perpetuates angiogenesis and inflammatory glycolysis. Fourth, aberrant proteolytic activity is manifested by marked overexpression of matrix metalloproteinases (MMP-2, MMP-3, MMP-9, and MMP-13), which not only degrade cartilage matrix but also provide enzyme-specific cleavage sites for targeted drug activation. Fifth, active cell death and stress responses in the inflamed joint lead to markedly elevated extracellular ATP concentrations, which act as damage-associated molecular patterns (DAMPs) that amplify inflammation via P2 receptor and NLRP3 inflammasome signaling. Finally, the lesion exhibits sustained elevation of pro-inflammatory cytokines (eg, TNF-α, IL-1β, IL-6) that dominate the local molecular milieu; these cytokines themselves can serve as direct stimuli for feedback-controlled drug release. These multifaceted microenvironmental characteristics—spanning pH, redox, enzymatic, hypoxic, purinergic, and cytokine signals—collectively provide distinct targets for the precise delivery and functional activation of therapeutic agents. The therapeutic strategy of regulating oxidative stress and inflammatory cytokine levels has emerged as a core focus in recent RA research. By converting these diverse microenvironmental features into therapeutic trigger signals, this approach enables precise drug accumulation, enzyme-activated prodrug conversion, hypoxia-driven disassembly, ATP-competitive payload release, and cytokine-responsive on-demand delivery within the lesion area. SPNs, with their designable structures and multi-responsiveness, serve as core carriers and technical enablers, achieving precise regulation of the RA inflammatory microenvironment. SPNs Loaded with Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Chen et al60 grafted water-soluble methoxy poly(ethylene glycol) (mPEG-COOH, Mn = 5000) onto water-insoluble BYG chains via a 1,1’-carbonyldiimidazole (CDI)-catalyzed esterification reaction. Using 3,3’-dithiodipropionic acid (DTPA) as a crosslinker, the carboxyl groups of DTPA were reacted with the 2-position hydroxyl groups of BYG-g-mPEG under CDI catalysis to form a disulfide-containing crosslinked copolymer (cBP). MTX was subsequently loaded into the resulting nanoparticles. Following intravenous administration, the nanoparticles preferentially accumulated in the inflamed joints of RA. After internalization by activated macrophages, GSH triggered the release of MTX. The released MTX inhibited the MAPK signaling pathway, leading to reduced production of pro-inflammatory cytokines, while simultaneously inducing the polarization of M1 macrophages toward the M2 phenotype. Moreover, the nanocarrier system reduced the systemic toxicity of MTX, thereby protecting the liver, kidneys, and joint structures. To further enhance the therapeutic synergy of csDMARDs, Negi et al75 designed a dual-drug co-delivery nano-system comprising MTX and aceclofenac (ACE). In this system, MTX was encapsulated within lipid–polymer hybrid nanoparticles (MTX-LPHNPs) composed of a polycaprolactone (PCL) core and a lipid shell of phospholipid 90G/cholesterol/DSPE-PEG-2000. Administered intravenously, MTX—a first-line disease-modifying antirheumatic drug (DMARD)—inhibits dihydrofolate reductase to block immune cell proliferation. Experimentally, it downregulated the PI3K–Akt pathway by reducing the level of p-Akt1 (by 60%), suppressed nuclear translocation of NF-κB p65 (by 55%), decreased iNOS expression (leading to a 40% reduction in NO production), and inhibited the LC3-II/LC3-I ratio (by 35%), a marker of autophagy, thereby promoting apoptosis of inflammatory cells. Meanwhile, ACE was loaded into nanostructured lipid carriers (ACE-NLCs) containing a chemical permeation enhancer (CE) and formulated as a topical gel (Gel-(ACE-NLCs+CE)). In an LPS-activated THP-1 macrophage model, this gel significantly suppressed COX-2 expression (by 58%), reduced prostaglandin E2 (PGE2) secretion (by 45%), and inhibited the release of pro-inflammatory cytokines IL-6 and TNF-α. The two drugs, administered via intravenous and transdermal routes respectively, acted synergistically to exert anti- RA effects. In addition to relying on GSH-responsive release, pH responsiveness also serves as a key design strategy for csDMARDs nanocarriers. For example, Kumar et al73 prepared folate-conjugated glycol-chitosan nanoparticles (MFGCN), which ingeniously utilize the targeting property of folate receptor β to achieve precise localization of activated macrophages. With a particle size of approximately 300 nm, these nanoparticles can release MTX in a pH-responsive manner under the acidic inflammatory microenvironment. In vitro experiments showed that MFGCN induces mitochondrial membrane potential disruption, production of ROS and reactive nitrogen species (RNS) in macrophages, thereby promoting cell apoptosis. In the adjuvant-induced arthritis (AIA) model, MFGCN effectively reduced serum levels of pro-inflammatory cytokines (TNF-α, IL-1β), enhanced antioxidant capacity, and significantly improved joint structural damage by targeting inflamed joint sites, demonstrating favorable therapeutic effects of combined targeted delivery and microenvironment modulation. Systemic administration of csDMARDs is prone to causing organ toxicity, so locally administered csDMARDs nanocarriers have also garnered significant attention. Siddiqui et al92 prepared a hydrogel loaded with folate (FA)-modified chitosan (CHI)-chondroitin sulfate (CHS) nanoparticles (FA-LEF-NPs), fully utilizing the specific binding of FA to FR-β receptors on macrophage surfaces to achieve active targeting. FA-LEF-NPs prepared via ion gelation not only have an appropriate particle size and high encapsulation efficiency but also can be efficiently internalized by LPS-activated RAW 264.7 macrophages, effectively inhibiting the release of inflammatory cytokines such as TNF-α and IL-1β. After transdermal administration, the hydrogel loaded with FA-LEF-NPs exhibited robust therapeutic efficacy in the CIA model, significantly reducing joint swelling and inflammatory cell infiltration, lowering serum inflammatory cytokine levels, and demonstrating good safety with no obvious toxicity to the liver or kidneys—achieving efficient and low-toxicity RA treatment. SPNs Loaded with Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) Yang et al simulated the “bottle-brush” structure of proteoglycans in synovial fluid to construct biomimetic nanoparticles (CS–CHI@DS) with both hydration lubrication and anti-inflammatory functions.93 Chitosan nanoparticles (CS NPs), with good biocompatibility and biodegradability, were utilized to load the anti-inflammatory drug diclofenac sodium (DS) via electrostatic interactions, while also providing grafting sites for chondroitin sulfate (CHI). Proteoglycans are glycoconjugates composed of proteins and glycosaminoglycans (chondroitin sulfate), linked by covalent bonds and produced by chondrocytes. Proteoglycans can assemble via their core proteins onto hyaluronic acid backbones, forming bottle-brush-like aggregates. Due to the presence of negatively charged sulfate groups, these aggregates exhibit excellent hydration and adsorption capacities, leading to superior lubrication properties on cartilage surfaces. CHI, a typical sulfated glycosaminoglycan found in synovial fluid and on cartilage surfaces, forms a dense hydration layer through interactions between its negatively charged groups and water molecules. This layer bears shear loads to prevent direct cartilage contact and wear, while also possessing cartilage repair and ROS scavenging capabilities. Experimental results demonstrated that CS–CHI@DS achieved scavenging rates of 37.9%, 37.9%, 44.2%, and 43.3% against DPPH radicals, H2O2, hydroxyl radicals (·OH), and superoxide anions (O2− ), respectively, which were significantly higher than those of CS NPs, indicating its potential to reduce ROS-mediated chondrocyte apoptosis and matrix degradation. SPNs for Load-Immune/Inflammation Modulators Xu et aldesigned a biomimetic multifunctional nanomedicine (M-M@I) precisely targeting the pathological features of RA: excessive ROS production, inflammatory response, and osteoclast differentiation. By loading the anti-inflammatory and anti-osteoclastogenic drug ibudilast (IGU) onto a ROS-scavenging mesoporous polydopamine (MPDA) carrier, then encapsulating it within macrophage membranes, the nanoparticles achieve active targeted delivery to inflamed joints.94 MPDA scavenges ROS, IGU suppresses inflammation and osteoclast differentiation, while macrophage membranes enable targeted delivery and prolonged circulation. This synergistic approach disrupts the vicious cycle of “ROS → inflammation → osteoclast differentiation,” significantly enhancing efficacy compared to monotherapy. In vitro experiments confirmed that M-M@I effectively scavenged reactive oxygen species, downregulated genes associated with inflammation and osteoclast differentiation, reduced levels of pro-inflammatory cytokines and osteoclast-related enzymes, and inhibited macrophage polarization toward the M1 phenotype. In the CIA mouse model, M-M@I accumulated at inflammatory sites and extended circulation time, significantly alleviating arthritis symptoms and bone destruction. This validated the efficacy of this multifunctional therapeutic strategy in simultaneously targeting multiple pathological processes. Similarly, some nanoplatforms (PAM-HA@Sin nanoparticles, and HA-NG) that can intelligently respond to ROS or GSH have also been designed to enable precise drug release.69,95,96 These strategies synergistically modulate the inflammatory microenvironment at different levels: HA-NG reduces toxicity to normal cells through GSH-responsive drug release; PAM-HA@Sin nanoparticles achieve combined antioxidant and anti-inflammatory therapy by responding to ROS. Based on a similar ROS regulation approach, targeted drug delivery for RA has been accomplished by engineering systems that respond to multiple pathological signals in the RA microenvironment. A triple-crosslinked hydrogel OD-PP@SeNPs with dual ROS/pH responsiveness was prepared by Wang et al95 At the site of inflammation, this hydrogel degrades and releases selenium nanoparticles (SeNPs). The nanoparticles inhibit PI3K phosphorylation and reduce Akt activation by activating the PI3K/Akt pathway; suppress NF-κB and MAPK signaling pathways by scavenging ROS (reducing upstream signals of MAPK activation); effectively promoting M1-to-M2 macrophage polarization. Following nanoparticle release, they downregulate osteoclast-specific gene expression, inhibit NFATc1 (a key osteoclast differentiation transcription factor), block RANKL/RANK/NFATc1 pathway activation, reduce osteoclastogenesis, and concurrently decrease ROS and inflammatory cytokine production. In Staphylococcus aureus-infected wounds and rheumatoid arthritis rat models, OD-PP@SeNPs not only accelerated wound healing but also significantly alleviated joint inflammation and bone erosion without systemic toxicity. This provides a multifunctional therapeutic platform for rheumatoid arthritis treatment, combining anti-inflammatory, antioxidant, and antibacterial properties. SPNs for Loading Gene Drugs (siRNA) Xie et al81 constructed a biomimetic co-delivery platform (MACP siTNF-α NPs) that uniquely combines nanozyme activity with gene therapy (Figure 6). This system features a Prussian blue (PB) nanozyme core loaded with TNF-α-targeting siRNA, sequentially coated with a guanidine-based polymer (AC) and macrophage membrane (MCM). This innovative design establishes a self-sustaining cycle of drug release, effectively linking ROS scavenging with anti-inflammatory action. The targeting mechanism relies on SR-B1 scavenger receptors, highly expressed on M1 macrophages, which recognize anionic phospholipids present on the nanoparticle’s membrane coating. Once internalized, the PB nanozyme decomposes ROS through iron valence cycling. While the membrane coating modestly reduced the CAT/SOD-like activity (lowering H2O2 scavenging to 13.17% and superoxide anion clearance to 28.45%), the nanoparticles demonstrated superior intracellular ROS clearance compared to free PB, owing to their enhanced cellular uptake. Concurrently, PB nanozyme activity restored intracellular GSH levels in M1 cells—by 2.3-fold at 100 μg/mL. This elevated GSH then triggered the degradation of the AC polymer, promoting siRNA release and further exposing PB nanozymes. This process creates a self-amplifying feedback loop: reduced ROS leads to increased GSH, which accelerates AC degradation and subsequent siRNA release and PB exposure, further reducing ROS levels. Flow cytometry data confirmed a significant shift in macrophage polarization following treatment. The M1 phenotype (CD86⁺) decreased from 74.4% to 50.9%, while the M2 population (CD206⁺) increased from 10.5% to 24.27%. The resulting M2/M1 ratio reached 0.48, representing a 6.3-fold increase over the model group. In summary, this nanoplatform operates through a multi-level therapeutic strategy: it clears ROS via the PB nanozyme, silences a key inflammatory mediator through siRNA, and promotes macrophage phenotype switching, collectively disrupting the RA pathological process by simultaneously targeting multiple pivotal pathways. Figure 6Mechanism of the biomimetic nanodelivery platform (MACP siTNF-α NPs) for rheumatoid arthritis treatment. The biomimetic nanodelivery platform reverses the macrophage ecological niche in inflammatory environments through a self-sustaining positive feedback drug release mechanism. Copyright (2025), reproduced with permission from Wiley-VCH Verlag.MACP siTNF-alpha NPs for arthritis: drug delivery, macrophage polarization, feedback mechanism.The diagram illustrates the mechanism of the biomimetic nanodelivery platform MACP siTNF-alpha NPs for rheumatoid arthritis treatment. It shows the synthesis of AC from AGM and CBA, forming ACP siTNF-alpha with Prussian blue and siTNF-alpha. This is coated with a macrophage cell membrane to form MACP siTNF-alpha. The platform is injected into a mouse model. The lower section details the cellular process: endocytic and phagocytic uptake of nanoparticles, lysosome escape and decomposition of reactive oxygen species. The process enhances intracellular GSH levels, leading to rapid degradation of AC and siRNA release. This creates a positive feedback mechanism, reducing reactive oxygen species and promoting macrophage polarization from M1 to M2, suppressing inflammatory factors like IL-1 beta and IL-6 and promoting tissue repair and homeostasis. The diagram highlights the complete exposure of Prussian blue and silencing of TNF-alpha expression. Mechanism of the biomimetic nanodelivery platform (MACP siTNF-α NPs) for rheumatoid arthritis treatment. The biomimetic nanodelivery platform reverses the macrophage ecological niche in inflammatory environments through a self-sustaining positive feedback drug release mechanism. Copyright (2025), reproduced with permission from Wiley-VCH Verlag. SPNs Loaded with Functional Materials (Without Traditional Drugs) Beyond passive ROS scavenging, engineered nanozymes can function as “messengers” that actively reprogram the inflammatory microenvironment. Jia et al97 designed a messenger nanozyme system that not only catalytically eliminates ROS but also modulates macrophage polarization and suppresses pro-inflammatory cytokine cascades, thereby disrupting the self-sustaining loop of oxidative stress and inflammation in RA. This paradigm illustrates how functional nanomaterials can serve as therapeutic entities in their own right, independent of traditional drug payloads. Simón-Vázquez et al98 reported the encapsulation of palmitate dexamethasone (DXP) into PLGA-PEG nanoparticles (DXP-NPs). The lipophilic nature of DXP facilitates its incorporation into the hydrophobic core of PLGA-PEG, achieving a drug loading capacity of 7.5%. Through the action of in vivo enzymes, DXP is gradually released and hydrolyzed into dexamethasone (DXM). DXM exerts its anti-inflammatory effects by inhibiting transcription factors such as NF-κB and AP-1, thereby blocking the MAPK signaling pathway and reducing the production of pro-inflammatory cytokines. The targeted delivery via DXP-NPs enhances the local concentration of DXM at inflammatory sites, improving anti-inflammatory efficacy. This approach prolongs the plasma half-life of DXM and reduces its distribution in non-target organs. In both ex vivo and in vivo experiments, DXP-NPs demonstrated superior therapeutic effects compared to free dexamethasone sodium phosphate (DSP), optimizing the pharmacokinetic profile and therapeutic outcome of the drug. In addition to prodrug modification strategies, optimizing the internal structure of nanocarriers is also an important research direction. Chlorogenic acid (CA), despite its known therapeutic potential in RA—mediated by inhibiting NF-κB and activating Nrf-2 pathways—it suffers from poor stability, a short half-life, and rapid in vivo clearance; meanwhile, conventional liposomal drug delivery systems suffer from inherent drawbacks such as prone to in vivo drug leakage, insufficient targeting capability, and poor stability. Therefore, Lin et al developed a novel alginate nanogel-embedded liposome system (LSHNPs) to address critical challenges in RA treatment.99 This nanosystem features a distinctive internal structural design: a Ca2⁺-crosslinked three-dimensional alginate network was incorporated into the internal aqueous phase of liposomes. Significantly, this modification enhanced particle rigidity by 2.6-fold without compromising the liposome’s surface properties (eg, PEGylation), thereby endowing LSHNPs with superior resistance to serum protein adsorption, enhanced tolerance to blood flow shear stress, and reduced drug leakage. Their results demonstrated that LSHNPs exhibited exceptional targeting ability and therapeutic efficacy in the arthritic microenvironment. Their optimized rigidity significantly promoted active endocytosis by inflammatory macrophages, and by regulating protein corona composition—specifically increasing apolipoprotein E (ApoE)/albumin adsorption while decreasing fibrinogen adsorption—LSHNPs extended in vivo blood circulation time by 2-fold. Upon intracellular entry, the internal gel network enabled sustained release of CA, which subsequently inhibited ROS production and the expression of pro-inflammatory cytokines (eg, tumor necrosis factor-α [TNF-α], interleukin-6 [IL-6]) via the NF-κB/Nrf-2 pathway. This mechanism effectively reversed macrophage M1 polarization and alleviated inflammatory infiltration. In a rat model of RA, LSHNPs completely suppressed joint swelling and significantly improved histopathological scores, thereby demonstrating excellent therapeutic efficacy. Therapeutic specificity can be enhanced through synergistic designs combining pH responsiveness with targeted modifications. A representative example is folate-modified carboxymethyl chitosan nanopolymers (SCNP), which also utilize pH-sensitive drug release within the acidic inflammatory microenvironment.100 This synergistically inhibits the NF-κB/NLRP3 pathway, effectively modulating the inflammatory microenvironment and alleviating RA symptoms. To address the complex inflammatory microenvironment of RA, another targeted nanoplatform (MPMAF) was developed. This platform utilizes folate (FA) to target folate receptors on M1 macrophages, enabling specific drug accumulation at inflammatory sites. This platform demonstrated triple therapeutic effects: it releases loaded drugs such as MTX to suppress pro-inflammatory cytokine production (TNF-α, IL-1β, IL-6) and promotes macrophage polarization from M1 to M2 type, thereby reducing inflammatory infiltration. Simultaneously, it leverages the inherent antioxidant properties of the carrier material (PDA) to directly scavenge excess ROS at the lesion site (eg, O2−, ·OH), mitigating oxidative stress-induced joint damage. Finally, the loaded drugs also directly suppress the expression of key osteoclast differentiation genes (NFATc1, c-Fos), collectively reducing bone erosion. Building on the concept of MMP-responsive polymer deshielding, a recent study developed MMP-sensitive macrophage-targeted nanoparticles (CoQ10-NPs) comprising an MMP-2/9-cleavable PEG–peptide–phosphatidylethanolamine (PEG-pp-PE) copolymer and phosphatidylserine (PS).101 When the molar ratio of the polymer to PS was 50:50, the CoQ10 loading was approximately 9.7%. The CoQ10-loaded nanoparticles had a particle size of less than 200 nm and a zeta potential of approximately −40 mV, and exhibited sustained drug release under simulated sedimentation conditions at 37 °C. Under normal physiological conditions, the PEG corona shielded the PS “eat-me” signal, minimizing nonspecific phagocytosis. Upon exposure to MMP-2/9 in the RA synovium, the peptide linker was enzymatically cleaved, leading to PEG deshielding and PS exposure, which triggered selective uptake by macrophages. The cellular uptake in RAW264.7 cells was 3.5-fold higher in the presence of MMPs than in their absence, and more than 13-fold higher than in fibroblasts, underscoring the exquisite macrophage selectivity of this enzyme-responsive design. The CoQ10-loaded NPs significantly inhibited pro-inflammatory cytokine production (TNF-α, IL-6, IL-1β) while enhancing anti-inflammatory IL-10 secretion. Wang et al developed an inflammatory stimulus‑responsive hyaluronic acid–triglycerol monostearate polymersome (HTDD) for the co‑delivery of 2‑DG (a glycolysis inhibitor) and dexamethasone to treat RA.102 The polymersomes were assembled from HA (5 kDa) conjugated with TGMS via a pH‑sensitive PBA linker, forming amphiphilic conjugates that self‑assembled into vesicular structures by thin‑film hydration (size ~178.6 nm, zeta potential –16.8 mV). Hydrophilic 2‑DG was encapsulated in the aqueous core, while hydrophobic Dex was embedded in the bilayer membrane, with encapsulation efficiencies of 12.3% and 72.5%, respectively. The system acts through a triple mechanism: ① 2‑DG inhibits glycolysis (downregulating 11 glycolytic genes including Hk3 and Eno1), cutting off the energy supply to inflammatory cells; ② Dex suppresses the NF‑κB pathway and counteracts 2‑DG‑induced ROS elevation, synergistically breaking the “inflammation–glycolysis” positive feedback loop; ③ HA mediates CD44‑targeted delivery to multiple inflammatory cell types, while acidic pH and overexpressed MMPs trigger polymersome disassembly and synchronous drug release (cumulative release increased from <40% at pH 7.4 to >70% at pH 5.5 + MMPs over 48 h). Compared with free drug combinations or monotherapies, HTDD significantly prolonged the half‑life and AUC of Dex, achieved ~3‑fold higher drug accumulation in inflamed joints versus normal joints, reduced arthritis scores in the AIA model, decreased CD4⁺ T‑cell and M1 macrophage infiltration, increased Treg proportions, and improved synovial pathology without hepatorenal toxicity. However, the drug loading capacity of 2-DG is only 1.2%, and its hydrophilic drug-loading capacity is severely insufficient, which affects clinical feasibility and the volume of administration. Data on long-term degradation behavior are lacking (only 48 hours in vitro); future efforts should focus on optimizing the structure-function relationship of the material, enhancing its hydrophilic drug-loading capacity, and establishing long-term toxicological evaluations. Structure–Property–Function Relationships of Smart Polymer Nanoparticles The therapeutic efficacy of SPNs in RA is governed not only by their stimulus-responsive functionality but also by fundamental physicochemical parameters—including polymer composition, molecular weight, architecture, degradability, and surface chemistry—that collectively determine targeting efficiency, drug release kinetics, and biological performance. A critical understanding of these structure–property–function relationships is essential for the rational design of next-generation nanomedicines. Polymer Composition and Molecular Weight The chemical identity and molecular weight (MW) of the constituent polymers dictate the hydrophobic/hydrophilic balance, self-assembly behavior, and drug compatibility of SPNs. For instance, poly(lactic-co-glycolic acid) (PLGA), the most widely used synthetic polyester in RA nanomedicine, exhibits degradation rates that scale inversely with lactide content and MW: PLGA 50:50 degrades within 1–2 months, whereas 85:15 formulations persist for 5–6 months.103 This tunability allows precise matching of release profiles to disease chronology. Higher-MW PLGA chains entangle more extensively, reducing initial burst release and extending the duration of therapeutic exposure.104 Conversely, low-MW chitosan (eg, <50 kDa) enhances mucoadhesion and transcytosis across inflamed synovial membranes but may compromise structural integrity during systemic transit. The optimal MW thus represents a trade-off between circulation stability and tissue penetration. Polymer Architecture: Dendrimers versus Hyperbranched Polymers The branching architecture of polymers profoundly influences drug payload capacity, release kinetics, and manufacturing scalability. Dendrimers, with their perfectly branched, monodisperse structures, offer precisely defined multivalency and high surface functional group density, enabling conjugation of multiple targeting ligands and drug molecules per particle.105 However, their stepwise synthesis is labor-intensive and costly. Hyperbranched polymers (HBPs), by contrast, are synthesized in a single-pot reaction and possess imperfect branching with greater conformational flexibility.106 Comparative studies using methylprednisolone as a model drug revealed that HBPs achieved higher drug payloads and faster intracellular release due to reduced steric crowding and enhanced lysosomal enzyme accessibility.107 Theoretically, HBP micelles also exhibit lower critical micelle concentrations and superior stability under dilution compared to dendrimer analogs, making them attractive for in vivo applications. For RA therapy, this architectural distinction is clinically relevant: dendrimers excel in applications requiring precise ligand spacing (eg, multivalent folate targeting), whereas HBPs are preferable for high-loading, cost-sensitive formulations. Degradability and Drug Release Kinetics Biodegradability is a double-edged sword in RA nanomedicine. While rapid degradation ensures clearance and minimizes foreign-body reactions, premature disassembly before reaching the synovium undermines therapeutic efficacy. PLGA degrades via bulk or surface hydrolysis of ester bonds, producing lactic and glycolic acids that are metabolized through the Krebs cycle; however, the acidic microenvironment generated during degradation can paradoxically exacerbate local inflammation if buffering strategies are not implemented. Natural polymers such as chitosan and hyaluronic acid degrade enzymatically (eg, via lysozyme or hyaluronidase), offering release profiles that are more closely coupled to the inflammatory milieu.108 The incorporation of stimuli-cleavable linkers—such as disulfide bonds for GSH-responsive release or MMP-cleavable peptides for enzyme-triggered activation—further decouples systemic stability from site-specific payload liberation, as detailed in subsequent sections. Surface Chemistry and the Protein Corona Upon intravenous administration, SPNs instantaneously adsorb plasma proteins to form a “protein corona” that constitutes the true biological identity of the particle. The composition of this corona—enriched in opsonins (eg, immunoglobulins, complement factors) versus dysopsonins (eg, albumin, apolipoproteins)—determines macrophage recognition, circulation half-life, and biodistribution.109 Surface PEGylation remains the gold standard for minimizing protein fouling and extending circulation. However, the stealth effect is not binary but depends critically on PEG grafting density and chain conformation. At low densities, PEG adopts a “mushroom” conformation (Flory radius R ≥ inter-graft distance D), providing limited steric protection. Only when PEG transitions to a “brush” conformation (R/D > 1) or, optimally, a “dense brush” regime (L > 2R, where L is the layer thickness) does effective suppression of macrophage uptake and protein adsorption occur.110,111 Nanoparticle Size, Shape, and Charge These geometric and electrostatic parameters collectively govern vascular extravasation, tissue penetration, and cellular internalization. Particles <50 nm undergo rapid renal filtration, whereas those >200 nm are preferentially sequestered by hepatic Kupffer cells; the optimal size window for RA targeting via the enhanced permeability and retention (EPR) effect and subsequent macrophage uptake lies between 100–200 nm.112 Shape exerts equally profound effects: rod-like or filamentous particles exhibit prolonged circulation and reduced macrophage internalization compared to spherical counterparts of equivalent volume, owing to impaired recognition by actin-driven phagocytosis machinery.113 Surface charge modulates both protein corona composition and direct electrostatic interactions with cell membranes. Cationic nanoparticles (ζ-potential > +30 mV) adsorb negatively charged plasma proteins (eg, albumin) and exhibit enhanced uptake by negatively charged macrophage membranes but suffer from rapid opsonization and hemolytic toxicity. Anionic or near-neutral surfaces (ζ ~ −10 to +10 mV) minimize nonspecific interactions while preserving colloidal stability.114 Nanoparticle Rigidity and Mechanical Properties An emerging yet critical parameter is nanoparticle elasticity, which influences protein corona formation, cellular uptake mechanisms, and circulation lifetime. Soft, deformable nanoparticles (eg, conventional liposomes) can traverse biological hydrogels and tight endothelial junctions more readily but are prone to disassembly under hemodynamic shear stress. Rigid nanoparticles, conversely, resist deformation and maintain structural integrity but may be recognized as “foreign bodies” by mechanosensitive phagocytic receptors.115 In the context of RA, Lin et al99 engineered alginate nanogel-embedded liposomes (LSHNPs) in which internal Ca2⁺-crosslinked alginate networks increased particle rigidity by 2.6-fold without altering surface PEGylation. This optimized rigidity promoted active endocytosis by inflammatory macrophages, altered protein corona composition (increasing ApoE/albumin adsorption while decreasing fibrinogen), and extended blood circulation time by 2-fold—directly translating to enhanced arthritic joint accumulation and therapeutic efficacy. These findings underscore that mechanical properties must be co-optimized with chemical functionality in SPN design. Comparison of Nanomedicine for RA Intra-SPN Comparative Analysis Among the systems reviewed, Chen et al60 and Kumar et al73 adopted single-drug strategies (MTX), achieving targeted therapy through GSH- or pH-triggered release. In contrast, Negi et al75 designed a dual-drug co-delivery system comprising MTX-LPHNPs and ACE-NLCs, acting synergistically via intravenous and transdermal routes. The theoretical advantage of dual-drug strategies lies in simultaneous blockade of distinct pathological pathways (MTX inhibits immune cell proliferation; ACE suppresses COX-2/PGE2), yielding synergistic anti-inflammatory effects. However, this comes at the cost of significantly increased formulation complexity—two distinct nanocarriers must be separately optimized for particle size, release kinetics, and stability, with risks of drug–drug interactions. Single-drug systems offer streamlined synthetic routes and superior batch-to-batch consistency but may be insufficient to address the multi-pathway complexity of RA. Most systems reviewed herein rely on passive accumulation via the EPR effect (eg, Chen et al)[60] However, MPS clearance eliminates 40–50% of nanoparticles within hours. Active targeting strategies substantially improve upon this limitation: Kumar et al73 (folate-modified MFGCN) and Siddiqui et al92 (FA-LEF-NPs) achieve 3–4-fold improved MTX delivery efficiency via folate–FR-β binding; Xu et al94 (M-M@I) and Xie et al81 (MACP siTNF-α NPs) employ macrophage membrane coating, leveraging native surface receptors (eg, LFA-1, CXCR2, SR-B1) for inflammatory homing with targeting efficiencies rivaling or exceeding chemical ligand modification. Nevertheless, active targeting introduces risks of immunogenicity and manufacturing complexity. SPNs versus Other Nanocarriers Different types of nanocarriers possess distinct advantages and disadvantages and exhibit differentiated application prospects in the clinical translation of targeted therapy for RA. Liposomes and solid lipid nanoparticles (SLNs) represent the most clinically mature nanocarriers, featuring excellent biocompatibility, scalable manufacturing capability, efficient metabolic clearance through natural lipid degradation pathways, and mild inflammatory responses. However, they are commonly plagued by low drug loading capacity, drug leakage during storage, and poor stability in serum environments. Relevant comparative studies have verified that polymer-based delivery systems, in contrast to rapidly releasing lipid formulations, enable sustained and slow drug release, thereby prolonging therapeutic duration and improving joint protection effects.116 SPNs compensate for many limitations of lipid carriers due to their superior structural integrity, precisely tunable degradation rates, and versatile surface functionalization for multiple modifications. Nevertheless, acidic byproducts such as lactic acid generated during SPN degradation may exacerbate local inflammation without adequate buffering treatment. Compared with SPNs, inorganic nanoparticles including gold, iron oxide, silica, and quantum dots exhibit unique photothermal conversion, magnetic targeting, and multimodal imaging functions that cannot be achieved by pure organic polymer carriers. However, these inorganic materials lack established in vivo biodegradation pathways, tend to accumulate long-term in organs such as the liver and spleen, and present unresolved toxicological risks, severely hindering their clinical translation.117,118 Biomimetic vesicle carriers represented by exosomes and cell membrane-coated nanoparticles inherit natural cellular structures, possessing outstanding biocompatibility, low immunogenicity, and inherent inflammatory homing capability, which enables inflammation-targeted drug delivery without hepatotoxicity.119 Even so, their large-scale clinical applications are bottlenecked by low isolation yield, high batch-to-batch heterogeneity, imperfect quality control systems, and inherently limited cargo-loading efficiency. Overall, SPNs demonstrate unique application merits attributed to their highly flexible chemical design and programmable stimulus-responsive performance. Theranostic Polymer Nanoparticles for Imaging-Guided RA Therapy Beyond conventional drug delivery, an emerging frontier in RA nanomedicine is the integration of diagnostic imaging with therapeutic intervention—theranostics—to enable real-time monitoring of disease progression, drug distribution, and treatment response. Chen et al120 pioneered this approach by engineering tocilizumab-conjugated polymer nanoparticles for NIR-II photoacoustic-imaging-guided therapy of RA. These polymeric nanoprobes enabled high-resolution visualization of swollen cartilage and synovial tissue in CIA models, allowing noninvasive tracking of disease development while simultaneously delivering anti-IL-6R therapy. Similarly, Xiao et al developed endogenous melanin nanoparticles (MNPs) conjugated with cyclic RGD peptide (MNP-PEG-RGD) as a photoacoustic imaging (PAI) contrast agent. In RA mouse models, this nanoplatform actively targeted αvβ3 integrins within 1 h post-injection, with signal intensity remarkably increased in arthritic joints—enabling earlier diagnosis than conventional imaging modalities. Critically, the platform permitted dynamic monitoring of etanercept therapeutic efficacy by PAI, with histological validation confirming correlation between imaging signals and disease regression.121 Gandhi and Shende122 further advanced this paradigm with anti-CD64 antibody-conjugated PLGA nanoparticles co-loaded with methotrexate and gold nanoparticles, creating a multimodal theranostic system that combines macrophage-targeted chemotherapy with CT imaging capabilities for traceable, targeted RA therapy. These theranostic polymer systems address a critical unmet need in RA management: the ability to noninvasively assess synovial inflammation heterogeneity, verify nanoparticle accumulation at inflamed sites, and adapt therapeutic regimens based on real-time imaging feedback. Challenges Within the field of RA treatment, precision modulation strategies represented by SPNs offer a novel paradigm to overcome the limitations of traditional therapies by targeting pathological pathways through multidimensional approaches (Table 1): At the macrophage level, SPNs leverage precise targeting capabilities to suppress macrophage overactivation, promote their polarization toward the M2 anti-inflammatory phenotype, and eliminate abnormally activated cells. This approach disrupts the macrophage-centric inflammatory network at its source, effectively halting the propagation of inflammation in RA. At the FLS level, SPNs leverage the responsive characteristics of the RA synovial microenvironment to specifically inhibit abnormal FLS proliferation, migration, and pro-inflammatory cytokine secretion. This reduces synovial hyperplasia and joint tissue erosion, mitigating the progression of structural damage in RA. At the level of regulating macrophage-fibroblast synergy, SPNs reshape their signaling interactions (eg, by blocking pro-inflammatory cytokine-mediated positive feedback loops), breaking the vicious cycle of “macrophage pro-inflammation → FLS activation.” This approach curbs RA progression by disrupting intercellular collaboration. Finally, at the microenvironmental level, SPNs leverage RA lesion characteristics like acidity and high ROS levels to achieve drug-responsive release. Simultaneously, they modulate inflammatory cytokine levels and clear oxidative stress byproducts, optimizing the local synovial immune microenvironment to create favorable conditions for cellular function recovery. The integration of these four synergistic regulatory approaches constitutes a “multi-targeted, precision-based” therapeutic paradigm for RA. This approach enhances drug concentration at the lesion site while reducing systemic toxicity, thereby effectively counteracting the multifaceted pathological complexity of RA. Despite their significant potential in basic research and animal studies for RA treatment, their clinical translation remains challenging. There is significant inter-individual heterogeneity among RA patients, encompassing pathophysiology, immune responses, metabolic pathways, and genetic background, which makes it difficult for the same treatment plans to be effective for all individuals. For instance, some patients respond well to conventional DMARDs such as MTX, whereas others show no response. Currently available biomarkers, such as rheumatoid factor (RF) and anti-CCP antibodies, lack sufficient sensitivity and specificity for predicting treatment response and stratifying disease subtypes, thereby hindering the achievement of true precision stratification and personalized therapy.123 Moreover, RA patients often present with multiple comorbidities (eg, cardiovascular disease, diabetes, osteoporosis), which may influence drug selection and dosage adjustment.124 Meanwhile, SPNs face three core challenges in transitioning from laboratory research to clinical application: manufacturing, clinical safety, and patient acceptance. In production, the challenge lies in achieving large-scale, low-cost standardized manufacturing to ensure consistent nanoparticle size and targeting properties across batches. Regarding safety, while animal studies have yielded promising results, long-term human use requires extended follow-up periods to assess potential issues such as immune rejection or organ accumulation. Patient acceptance presents another concern, as current SPN delivery methods primarily involve intravenous or intra-articular injections. Intravenous administration may cause puncture pain and infection risks, while intra-articular injections require specialized medical personnel and frequent dosing, leading to reduced patient compliance. Table 1Comprehensive Summary of Smart Polymer Nanoparticles for Rheumatoid Arthritis TherapyNanoparticleCategoryCompositionPayloadTargeting LigandPhysicochemical ParametersStimulus ResponseMechanism/TargetRouteModelTherapeutic OutcomeRef.MacrophagesOCF/siHMGB1Macrophage-targetingOxidized CS-chitosan-β-GP-Fn hydrogelsiHMGB1—Hydrogel system (no discrete NP size reported)Thermo-gelation, self-healing↓HMGB1/TLR4/NF-κB; M1→M2; ↑IL-10, Arg-1Intra-articularCIAAlleviated RA; ↓IL-1β, TNF-α; ↑IL-10[59]cBPMMacrophage-targetingBYG-g-mPEG, DTPA crosslinkedMTXβ-glucan (Dectin-1)cBP: ~52.9 nm; cBPM: ~348 nm; Zeta: −14.9 ± 0.31 mV; DL: 23.7%GSH-responsive (disulfide)↓ERK1/2, p38 MAPK; ↓NF-κB, AP-1; ↓TNF-α, IL-1β, IL-6, iNOS, COX-2; M1→M2i.v.CIAAnti-inflammatory; M2 polarization; ↓NO[60]FP/miR-23bMacrophage-targetingGen-5 PAMAM, heptafluorobutyric anhydridemiR-23bFluorinationN/P 2.0: ~230.0 nmElectrostatic complex↓TAB2, TAB3, IKKA; ↓NF-κB; M1 apoptosis; ↓TNF-α, IL-1β—RA modelAlleviated RA; cytokine reduction; M1 apoptosis[61]FP/miR-30aMacrophage-targetingGen-5 PAMAM, heptafluorobutyric anhydridemiR-30aFluorination—Electrostatic complex↓Snai1; ↓NF-κB and MAPK; ↓cytokines—RA modelSignificant RA symptom relief[62]C17P10/siTNF-αMacrophage-targetingAmphiphilic phosphorus dendrimer C17P10TNF-α siRNA—223.2 ± 26.2 nmElectrostatic complexTNF-α silencing—CIA↓TNF-α; ↓synovial hyperplasia; ↓arthritis score[63]PEI-PDA@C-176Macrophage-targetingPEI-PDA mesoporous nanoparticlesC-176 + dsDNA——dsDNA adsorption↓STING pathway; ↓IFNβ, TNF-α, IL-6—Multiple arthritisAlleviated joint damage; good biocompatibility[64]R4F-NM@F127-CelMacrophage-targetingNeutrophil membrane + F127 + R4F peptideCelastrolNeutrophil membrane + R4F (SR-B1)NM@F127: 48.1 ± 5.8 nm, Zeta −2.8 ± 0.5 mV, PDI 0.08; R4F-NM@F127: 51.3 ± 2.1 nm, Zeta −3.1 ± 0.5 mV, PDI 0.078Inflammatory homing↓M1 polarization; ↑M2; ↓cytokines; low hepatotoxicity—CIA↓Joint inflammation and bone erosion; ↓serum cytokines[65]MPMAFMacrophage-targetingPDA-coated MnO2, FA & TNFα-Apt modifiedMTXFA (FR) + TNFα-Apt—MnO2/O2 generation; PDA/ROS scavenging; PTT↓NF-κB/NLRP3; ↓pro-inflammatory cytokines; M2 polarization; hypoxia relief—CIAAmeliorated joint inflammation and bone erosion[66]MPSNPrMacrophage-targetingMacrophage phenotype-specific nanoprobeBA/SAL screeningH-aggregate (GLUT1)—GLUT1 binding (M1-specific)High-throughput screening; Dex-SAL promotes M2—CIADex-SAL alleviated joint inflammation and cartilage destruction[67]ALG@SrR-MoS2-PpyMacrophage-targetingALG + MoS2 nanoflowers + PpySrR——NIR photothermal/photoelectricNIR activates HSPs; M2 polarization; ROS scavengingTransdermalZymosan RAAlleviated inflammation; ↓ROS & cytokines; improved joint structure[68]PAM-HA@SinMacrophage-targetingPAM-HA (PEG-Ald-Met modified HA)SinomenineHA backbone—ROS-responsive disassembly↓NF-κB; ↓pro-inflammatory; ↑anti-inflammatory; joint lubrication; ROS scavengingIntra-articularCIAProlonged joint retention; ↓swelling and cartilage destruction[69]CPG@T-GMacrophage-targetingCS-based nanocarrierGlcN + TofacitinibCS (CD44)—pH + ROS dual-responsiveTof: JAK/STAT inhibition; GlcN: cartilage repair; ROS consumption; M1→M2—CIASynergistic anti-inflammatory; cartilage repair[70]FA-TP@VAMacrophage-targetingPegylated retinoic acid + FATriptolideFA192.7 ± 4.4 nm; DL: 79.8 ± 5.1% (retinoate), 6.8 ± 0.1% (TP)Receptor-mediated endocytosis↓IL-1β (58%), IL-6 (42%), TNF-α (60%); ↓NFATc1 mRNA (65%), c-Fos, MMP-9——Superior to free TP (30–45%); mitigated bone erosion[71]MFGCNMacrophage-targetingFolate-glycol chitosanMTXFA (FR-β)~300 nmpH-responsiveMitochondrial disruption; ROS/RNS; macrophage apoptosis; ↓NF-κBi.v.AIA↓TNF-α, IL-1β; enhanced antioxidant; improved joint structure[73]MTX-LPHNPs + ACE-NLCsMacrophage-targetingPCL core + lipid shell / NLCs with CEMTX + Aceclofenac—MTX-LPHNPs: 168.5 ± 8.5 nm, PDI 0.11; ACE-NLCs: 189.9 ± 7.2 nm, PDI 0.19; Zeta: −4.0 to −18.0 mV—MTX: ↓DHFR, PI3K-Akt (p-Akt1↓60%), NF-κB p65 (↓55%), iNOS, NO↓40%, autophagy↓35%; ACE: ↓COX-2 (58%), PGE2↓45%i.v. + transdermalRA ratRestored paw bone and joint; comparable to commercial[75]PPy-FePi-MTXMacrophage-targetingPPy-FePi-MTXMTX—PPy-Fe: 153.0 nm; PPy-Fe-MTX: 165.3 nm; PPy-FePi-MTX: 177.0 nm; Zeta: −1.2 mV; MTX DL: 9.98%; Fe: 0.51%Inflammatory microenv. + NIR + GSHMTX apoptosis; NIR photothermal; Fenton reaction ferroptosis; PO43− lysosomal pH disruption—CIA↓Joint swelling, cytokines, bone erosion; multi-mechanism synergy[76]Gel/FA-PDA@LeonMacrophage-targetingHA hydrogel + FA-PDA NPsLeonFA (macrophage)PDA: 149.3 nm, Zeta −37.2 mV; PPF (FA-PDA): 220.5 nm, Zeta −26.7 mVIn situ gelation + bioadhesion↓JAK2/STAT3; ↓pro-inflammatory; regulates ferroptosis/ferritinophagy; chondrocyte protectionIntra-articularCIA↓Swelling; ↓inflammation score; joint function recovery; no systemic toxicity[77]Fibroblast-Like SynoviocytesFAP-ZF-NPsFLS-targetingZinc ferrite (ZF)— (magnetic hyperthermia)FAP peptideZF-NPs: 31.3 ± 1.8 nm, Zeta +10.5 ± 0.2 mV; FAP-ZF-NPs: 71.8 ± 2.9 nm, Zeta +20.9 ± 0.3 mVAMF (42°C)ERS activation + mitochondrial dysfunction + magnetothermal; 3.2× enrichment—RA modelEliminated FAP⁺ FLS; ↓synovial inflammation and bone erosion; good safety[83]HAP-1NPDC+LNDFLS-targetingHAP-1 peptide-modified carrierDC + LonidamineHAP-1 peptide—Prodrug releaseSynergistic glycolysis inhibition: DC↓GLUT-1, LND↓HK-2; prevents compensatory upregulation; cuts FLS energy supply—RA modelGLUT-1↓72%; HK-2↓68%; CD86⁺↓65%; FAP-α⁺↓70%; protected bone and cartilage[84]NanoIGUR hydrogelFLS-targetingPVA + HS-PEG-SH 3D networkNano-irinotecan——Gel-controlled release↓RA-FLS proliferation, migration (22.42%), invasion (20.74%); ↓MMP expressionSubcutaneousRA modelMigration & invasion lower than free drug (44.69%/44.59%); improved bioavailability[85]Macrophage–Synovial Fibroblast CrosstalkHP@CELCrosstalk remodelingHA-PCL copolymer hydrogelCelastrol— (biomimetic synovial lipid-HA)P@CEL: ~146 nm, PDI 0.24Local sustained release↓TLR4/NF-κB; ↓M1 polarization and FLS proliferation; blocks inflammatory positive feedbackLocal injectionCIAAlleviated inflammation and bone erosion; promoted cartilage matrix repair; excellent biocompatibility[89]APPC/pHO-1Crosstalk remodelingAR + CS-PEI + PSSHSP70-driven HO-1 plasmidCS-PEI (CD44)—NIR (808 nm) → heat → HSP70 promoterHO-1 overexpression: ↓glycolysis, anti-inflammatory polarization; simultaneously modulates macrophages and FLS; blocks cross-cellular signaling—RA modelMacrophage TNF-α/IL-6↓60%; FLS GLUT1/HK2↓45%; MMP9↓58%; iNOS↓52%; CD206↑2.8×; 40% greater efficacy than single-cell targeting[90]MCDsCrosstalk remodelingMetformin-derived carbon dots (-OH, -NH2, C=O; 15.90% N-doping)— (functional material)——Enzyme-like catalysis + electron transferROS scavenging; ↑SOD/CAT; ↓NLRP3; M1→M2; ↓FLS α-SMA, Col-I, TNF-α, IL-6; promotes FLS apoptosis—RA modelSynergistic ROS-M2-FLS homeostasis; alleviated inflammation; protected osteochondral; inhibited synovial fibrosis[91]Microenvironment-ResponsiveFA-LEF-NPs gelMicroenvironment-responsiveFA-modified chitosan-chondroitin sulfateLeflunomideFA (FR-β)Appropriate size; Zeta: +24.6 mV; High EEFA active targeting↓TNF-α, IL-1β releaseTransdermalCIA↓Joint swelling and inflammatory infiltration; ↓serum cytokines; no hepato/renal toxicity[92]CS–CHI@DSMicroenvironment-responsiveCS nanoparticles + CHI graftingDiclofenac sodiumCHI (proteoglycan mimic)210 nm; Zeta: +33 mVBiomimetic lubricationScavenges DPPH (37.9%), H2O2 (37.9%), ·OH (44.2%), O2− (43.3%); reduces ROS-mediated chondrocyte apoptosis and matrix degradation; hydration lubricationIntra-articular—Superior ROS clearance vs CS NPs; cartilage protection and repair[93]M-M@IMicroenvironment-responsiveMPDA + macrophage membraneIbudilastMacrophage membrane (inflammatory homing)—Active targeting + prolonged circulationMPDA scavenges ROS; IGU suppresses inflammation and osteoclast differentiation; breaks ROS→inflammation→osteoclast vicious cyclei.v.CIAInflammatory site accumulation; extended circulation; alleviated arthritis and bone destruction[94]OD-PP@SeNPsMicroenvironment-responsiveRedox/pH dual-responsive polymerSelenium nanoparticles—SeNPs: 57.4 ± 2.3 nm, Zeta +10.7 ± 3.0 mV, PDI 0.206Dual ROS/pH-responsive degradationSeNPs: ↓PI3K phosphorylation; ROS scavenging ↓MAPK upstream; ↓NF-κB/MAPK; M1→M2; ↓NFATc1 blocks RANKL/RANK/NFATc1TopicalRA rat + S. aureus woundAccelerated wound healing; alleviated inflammation and bone erosion; no systemic toxicity; anti-inflammatory + antioxidant + antibacterial[95]HA-NG/TACMicroenvironment-responsivePolyamino acid nanogelTacrolimusHA (CD44)—GSH-responsive release↓Normal cell toxicity; precise release———[95]MACP siTNF-α NPsMicroenvironment-responsivePB nanozyme + AC polymer + MCMTNF-α siRNAMCM (SR-B1 recognizes anionic phospholipids)—GSH-triggered AC degradation (self-amplifying: ROS↓→GSH↑→AC degradation→siRNA release→ROS further↓)PB nanozyme clears ROS (CAT/SOD-like); siRNA silences TNF-α; promotes M1→M2—RA modelGSH restored 2.3×; M1 (CD86⁺) 74.4%→50.9%; M2 (CD206⁺) 10.5%→24.27%; M2/M1=0.48 (6.3×)[81]DXP-NPsMicroenvironment-responsivePLGA-PEGPalmitate dexamethasone—DL: 7.5%In vivo enzymatic releaseDXM: ↓NF-κB, AP-1; blocks MAPK; ↓pro-inflammatory cytokines—Ex vivo / in vivoSuperior to free DSP; prolonged plasma half-life; reduced non-target organ distribution[98]LSHNPsMicroenvironment-responsiveLiposome with internal Ca2⁺-crosslinked alginate gelChlorogenic acid— (rigidity-tuned protein corona)Rigidity enhanced 2.6×; Circulation prolonged 2×Enhanced endocytosis + gel sustained releaseCA: ↓NF-κB/Nrf-2; ↓ROS, TNF-α, IL-6; reverses M1; tunes protein corona (ApoE/albumin↑, fibrinogen↓)i.v.RA ratComplete suppression of joint swelling; significantly improved histopathology; excellent targeting[99]SCNPMicroenvironment-responsiveCarboxymethyl chitosan + FASinomenine-curcuminFA—pH-sensitive release↓NF-κB/NLRP3 pathway——Modulated inflammatory microenvironment; alleviated RA symptoms[100]CoQ10-NPsMicroenvironment-responsiveMMP-2/9-cleavable PEG-pp-PE + PSCoenzyme Q10PS (exposed after MMP cleavage)Size: <200 nm; Zeta: ~−40 mV; DL: ~9.7%MMP-2/9 enzymatic PEG deshielding → PS exposure → macrophage uptake↓TNF-α, IL-6, IL-1β; ↑IL-10——RAW264.7 uptake: 3.5× with MMP vs without; 13× vs fibroblasts[101]HTDDMicroenvironment-responsiveHA (5 kDa)-TGMS, pH-sensitive PBA linker2-DG (hydrophilic) + Dex (hydrophobic)HA (CD44)Size: ~178.6 nm; Zeta: −16.8 mV; 2-DG EE: 12.3%, DL: 1.2%; Dex EE: 72.5%pH 5.5 + MMP overexpression triggers disassembly2-DG: ↓glycolysis (11 genes incl. Hk3, Eno1); Dex: ↓NF-κB and counteracts 2-DG-induced ROS; breaks inflammation-glycolysis loopi.v.AIAProlonged Dex half-life and AUC; ~3× accumulation in inflamed vs normal joints; ↓arthritis score; ↓CD4⁺ T & M1; ↑Treg; improved synovial pathology; no hepato/renal toxicity[102]Abbreviations: CS, chondroitin sulfate; BYG, yeast β-glucan; PAMAM, polyamidoamine; MTX, methotrexate; GlcN, glucosamine; Tof, tofacitinib; FA, folate; FR, folate receptor; PTT, photothermal therapy; i.v., intravenous; CIA, collagen-induced arthritis; AIA, adjuvant-induced arthritis; FAP, fibroblast activation protein; ZF, zinc ferrite; AMF, alternating magnetic field; ERS, endoplasmic reticulum stress; DC, diclofenac prodrug; LND, lonidamine; GLUT-1, glucose transporter 1; HK-2, hexokinase 2; PVA, polyvinyl alcohol; HA, hyaluronic acid; PCL, polycaprolactone; AR, gold nanorods; CS-PEI, chitosan-polyethyleneimine; PSS, polystyrene sulfonate; HO-1, heme oxygenase-1; NIR, near-infrared; MCDs, metformin-derived carbon dots; MPDA, mesoporous polydopamine; IGU, ibudilast; PB, Prussian blue; AC, guanidine-based polymer; MCM, macrophage cell membrane; SR-B1, scavenger receptor class B type 1; DXM, dexamethasone; DSP, dexamethasone sodium phosphate; ApoE, apolipoprotein E; 2-DG, 2-deoxyglucose; Dex, dexamethasone; TGMS, triglycerol monostearate; PBA, phenylboronic acid; DL, drug loading; EE, encapsulation efficiency; PDI, polydispersity index. Table 1Comprehensive Summary of Smart Polymer Nanoparticles for Rheumatoid Arthritis TherapyNanoparticleCategoryCompositionPayloadTargeting LigandPhysicochemical ParametersStimulus ResponseMechanism/TargetRouteModelTherapeutic OutcomeRef.MacrophagesOCF/siHMGB1Macrophage-targetingOxidized CS-chitosan-β-GP-Fn hydrogelsiHMGB1—Hydrogel system (no discrete NP size reported)Thermo-gelation, self-healing↓HMGB1/TLR4/NF-κB; M1→M2; ↑IL-10, Arg-1Intra-articularCIAAlleviated RA; ↓IL-1β, TNF-α; ↑IL-10[59]cBPMMacrophage-targetingBYG-g-mPEG, DTPA crosslinkedMTXβ-glucan (Dectin-1)cBP: ~52.9 nm; cBPM: ~348 nm; Zeta: −14.9 ± 0.31 mV; DL: 23.7%GSH-responsive (disulfide)↓ERK1/2, p38 MAPK; ↓NF-κB, AP-1; ↓TNF-α, IL-1β, IL-6, iNOS, COX-2; M1→M2i.v.CIAAnti-inflammatory; M2 polarization; ↓NO[60]FP/miR-23bMacrophage-targetingGen-5 PAMAM, heptafluorobutyric anhydridemiR-23bFluorinationN/P 2.0: ~230.0 nmElectrostatic complex↓TAB2, TAB3, IKKA; ↓NF-κB; M1 apoptosis; ↓TNF-α, IL-1β—RA modelAlleviated RA; cytokine reduction; M1 apoptosis[61]FP/miR-30aMacrophage-targetingGen-5 PAMAM, heptafluorobutyric anhydridemiR-30aFluorination—Electrostatic complex↓Snai1; ↓NF-κB and MAPK; ↓cytokines—RA modelSignificant RA symptom relief[62]C17P10/siTNF-αMacrophage-targetingAmphiphilic phosphorus dendrimer C17P10TNF-α siRNA—223.2 ± 26.2 nmElectrostatic complexTNF-α silencing—CIA↓TNF-α; ↓synovial hyperplasia; ↓arthritis score[63]PEI-PDA@C-176Macrophage-targetingPEI-PDA mesoporous nanoparticlesC-176 + dsDNA——dsDNA adsorption↓STING pathway; ↓IFNβ, TNF-α, IL-6—Multiple arthritisAlleviated joint damage; good biocompatibility[64]R4F-NM@F127-CelMacrophage-targetingNeutrophil membrane + F127 + R4F peptideCelastrolNeutrophil membrane + R4F (SR-B1)NM@F127: 48.1 ± 5.8 nm, Zeta −2.8 ± 0.5 mV, PDI 0.08; R4F-NM@F127: 51.3 ± 2.1 nm, Zeta −3.1 ± 0.5 mV, PDI 0.078Inflammatory homing↓M1 polarization; ↑M2; ↓cytokines; low hepatotoxicity—CIA↓Joint inflammation and bone erosion; ↓serum cytokines[65]MPMAFMacrophage-targetingPDA-coated MnO2, FA & TNFα-Apt modifiedMTXFA (FR) + TNFα-Apt—MnO2/O2 generation; PDA/ROS scavenging; PTT↓NF-κB/NLRP3; ↓pro-inflammatory cytokines; M2 polarization; hypoxia relief—CIAAmeliorated joint inflammation and bone erosion[66]MPSNPrMacrophage-targetingMacrophage phenotype-specific nanoprobeBA/SAL screeningH-aggregate (GLUT1)—GLUT1 binding (M1-specific)High-throughput screening; Dex-SAL promotes M2—CIADex-SAL alleviated joint inflammation and cartilage destruction[67]ALG@SrR-MoS2-PpyMacrophage-targetingALG + MoS2 nanoflowers + PpySrR——NIR photothermal/photoelectricNIR activates HSPs; M2 polarization; ROS scavengingTransdermalZymosan RAAlleviated inflammation; ↓ROS & cytokines; improved joint structure[68]PAM-HA@SinMacrophage-targetingPAM-HA (PEG-Ald-Met modified HA)SinomenineHA backbone—ROS-responsive disassembly↓NF-κB; ↓pro-inflammatory; ↑anti-inflammatory; joint lubrication; ROS scavengingIntra-articularCIAProlonged joint retention; ↓swelling and cartilage destruction[69]CPG@T-GMacrophage-targetingCS-based nanocarrierGlcN + TofacitinibCS (CD44)—pH + ROS dual-responsiveTof: JAK/STAT inhibition; GlcN: cartilage repair; ROS consumption; M1→M2—CIASynergistic anti-inflammatory; cartilage repair[70]FA-TP@VAMacrophage-targetingPegylated retinoic acid + FATriptolideFA192.7 ± 4.4 nm; DL: 79.8 ± 5.1% (retinoate), 6.8 ± 0.1% (TP)Receptor-mediated endocytosis↓IL-1β (58%), IL-6 (42%), TNF-α (60%); ↓NFATc1 mRNA (65%), c-Fos, MMP-9——Superior to free TP (30–45%); mitigated bone erosion[71]MFGCNMacrophage-targetingFolate-glycol chitosanMTXFA (FR-β)~300 nmpH-responsiveMitochondrial disruption; ROS/RNS; macrophage apoptosis; ↓NF-κBi.v.AIA↓TNF-α, IL-1β; enhanced antioxidant; improved joint structure[73]MTX-LPHNPs + ACE-NLCsMacrophage-targetingPCL core + lipid shell / NLCs with CEMTX + Aceclofenac—MTX-LPHNPs: 168.5 ± 8.5 nm, PDI 0.11; ACE-NLCs: 189.9 ± 7.2 nm, PDI 0.19; Zeta: −4.0 to −18.0 mV—MTX: ↓DHFR, PI3K-Akt (p-Akt1↓60%), NF-κB p65 (↓55%), iNOS, NO↓40%, autophagy↓35%; ACE: ↓COX-2 (58%), PGE2↓45%i.v. + transdermalRA ratRestored paw bone and joint; comparable to commercial[75]PPy-FePi-MTXMacrophage-targetingPPy-FePi-MTXMTX—PPy-Fe: 153.0 nm; PPy-Fe-MTX: 165.3 nm; PPy-FePi-MTX: 177.0 nm; Zeta: −1.2 mV; MTX DL: 9.98%; Fe: 0.51%Inflammatory microenv. + NIR + GSHMTX apoptosis; NIR photothermal; Fenton reaction ferroptosis; PO43− lysosomal pH disruption—CIA↓Joint swelling, cytokines, bone erosion; multi-mechanism synergy[76]Gel/FA-PDA@LeonMacrophage-targetingHA hydrogel + FA-PDA NPsLeonFA (macrophage)PDA: 149.3 nm, Zeta −37.2 mV; PPF (FA-PDA): 220.5 nm, Zeta −26.7 mVIn situ gelation + bioadhesion↓JAK2/STAT3; ↓pro-inflammatory; regulates ferroptosis/ferritinophagy; chondrocyte protectionIntra-articularCIA↓Swelling; ↓inflammation score; joint function recovery; no systemic toxicity[77]Fibroblast-Like SynoviocytesFAP-ZF-NPsFLS-targetingZinc ferrite (ZF)— (magnetic hyperthermia)FAP peptideZF-NPs: 31.3 ± 1.8 nm, Zeta +10.5 ± 0.2 mV; FAP-ZF-NPs: 71.8 ± 2.9 nm, Zeta +20.9 ± 0.3 mVAMF (42°C)ERS activation + mitochondrial dysfunction + magnetothermal; 3.2× enrichment—RA modelEliminated FAP⁺ FLS; ↓synovial inflammation and bone erosion; good safety[83]HAP-1NPDC+LNDFLS-targetingHAP-1 peptide-modified carrierDC + LonidamineHAP-1 peptide—Prodrug releaseSynergistic glycolysis inhibition: DC↓GLUT-1, LND↓HK-2; prevents compensatory upregulation; cuts FLS energy supply—RA modelGLUT-1↓72%; HK-2↓68%; CD86⁺↓65%; FAP-α⁺↓70%; protected bone and cartilage[84]NanoIGUR hydrogelFLS-targetingPVA + HS-PEG-SH 3D networkNano-irinotecan——Gel-controlled release↓RA-FLS proliferation, migration (22.42%), invasion (20.74%); ↓MMP expressionSubcutaneousRA modelMigration & invasion lower than free drug (44.69%/44.59%); improved bioavailability[85]Macrophage–Synovial Fibroblast CrosstalkHP@CELCrosstalk remodelingHA-PCL copolymer hydrogelCelastrol— (biomimetic synovial lipid-HA)P@CEL: ~146 nm, PDI 0.24Local sustained release↓TLR4/NF-κB; ↓M1 polarization and FLS proliferation; blocks inflammatory positive feedbackLocal injectionCIAAlleviated inflammation and bone erosion; promoted cartilage matrix repair; excellent biocompatibility[89]APPC/pHO-1Crosstalk remodelingAR + CS-PEI + PSSHSP70-driven HO-1 plasmidCS-PEI (CD44)—NIR (808 nm) → heat → HSP70 promoterHO-1 overexpression: ↓glycolysis, anti-inflammatory polarization; simultaneously modulates macrophages and FLS; blocks cross-cellular signaling—RA modelMacrophage TNF-α/IL-6↓60%; FLS GLUT1/HK2↓45%; MMP9↓58%; iNOS↓52%; CD206↑2.8×; 40% greater efficacy than single-cell targeting[90]MCDsCrosstalk remodelingMetformin-derived carbon dots (-OH, -NH2, C=O; 15.90% N-doping)— (functional material)——Enzyme-like catalysis + electron transferROS scavenging; ↑SOD/CAT; ↓NLRP3; M1→M2; ↓FLS α-SMA, Col-I, TNF-α, IL-6; promotes FLS apoptosis—RA modelSynergistic ROS-M2-FLS homeostasis; alleviated inflammation; protected osteochondral; inhibited synovial fibrosis[91]Microenvironment-ResponsiveFA-LEF-NPs gelMicroenvironment-responsiveFA-modified chitosan-chondroitin sulfateLeflunomideFA (FR-β)Appropriate size; Zeta: +24.6 mV; High EEFA active targeting↓TNF-α, IL-1β releaseTransdermalCIA↓Joint swelling and inflammatory infiltration; ↓serum cytokines; no hepato/renal toxicity[92]CS–CHI@DSMicroenvironment-responsiveCS nanoparticles + CHI graftingDiclofenac sodiumCHI (proteoglycan mimic)210 nm; Zeta: +33 mVBiomimetic lubricationScavenges DPPH (37.9%), H2O2 (37.9%), ·OH (44.2%), O2− (43.3%); reduces ROS-mediated chondrocyte apoptosis and matrix degradation; hydration lubricationIntra-articular—Superior ROS clearance vs CS NPs; cartilage protection and repair[93]M-M@IMicroenvironment-responsiveMPDA + macrophage membraneIbudilastMacrophage membrane (inflammatory homing)—Active targeting + prolonged circulationMPDA scavenges ROS; IGU suppresses inflammation and osteoclast differentiation; breaks ROS→inflammation→osteoclast vicious cyclei.v.CIAInflammatory site accumulation; extended circulation; alleviated arthritis and bone destruction[94]OD-PP@SeNPsMicroenvironment-responsiveRedox/pH dual-responsive polymerSelenium nanoparticles—SeNPs: 57.4 ± 2.3 nm, Zeta +10.7 ± 3.0 mV, PDI 0.206Dual ROS/pH-responsive degradationSeNPs: ↓PI3K phosphorylation; ROS scavenging ↓MAPK upstream; ↓NF-κB/MAPK; M1→M2; ↓NFATc1 blocks RANKL/RANK/NFATc1TopicalRA rat + S. aureus woundAccelerated wound healing; alleviated inflammation and bone erosion; no systemic toxicity; anti-inflammatory + antioxidant + antibacterial[95]HA-NG/TACMicroenvironment-responsivePolyamino acid nanogelTacrolimusHA (CD44)—GSH-responsive release↓Normal cell toxicity; precise release———[95]MACP siTNF-α NPsMicroenvironment-responsivePB nanozyme + AC polymer + MCMTNF-α siRNAMCM (SR-B1 recognizes anionic phospholipids)—GSH-triggered AC degradation (self-amplifying: ROS↓→GSH↑→AC degradation→siRNA release→ROS further↓)PB nanozyme clears ROS (CAT/SOD-like); siRNA silences TNF-α; promotes M1→M2—RA modelGSH restored 2.3×; M1 (CD86⁺) 74.4%→50.9%; M2 (CD206⁺) 10.5%→24.27%; M2/M1=0.48 (6.3×)[81]DXP-NPsMicroenvironment-responsivePLGA-PEGPalmitate dexamethasone—DL: 7.5%In vivo enzymatic releaseDXM: ↓NF-κB, AP-1; blocks MAPK; ↓pro-inflammatory cytokines—Ex vivo / in vivoSuperior to free DSP; prolonged plasma half-life; reduced non-target organ distribution[98]LSHNPsMicroenvironment-responsiveLiposome with internal Ca2⁺-crosslinked alginate gelChlorogenic acid— (rigidity-tuned protein corona)Rigidity enhanced 2.6×; Circulation prolonged 2×Enhanced endocytosis + gel sustained releaseCA: ↓NF-κB/Nrf-2; ↓ROS, TNF-α, IL-6; reverses M1; tunes protein corona (ApoE/albumin↑, fibrinogen↓)i.v.RA ratComplete suppression of joint swelling; significantly improved histopathology; excellent targeting[99]SCNPMicroenvironment-responsiveCarboxymethyl chitosan + FASinomenine-curcuminFA—pH-sensitive release↓NF-κB/NLRP3 pathway——Modulated inflammatory microenvironment; alleviated RA symptoms[100]CoQ10-NPsMicroenvironment-responsiveMMP-2/9-cleavable PEG-pp-PE + PSCoenzyme Q10PS (exposed after MMP cleavage)Size: <200 nm; Zeta: ~−40 mV; DL: ~9.7%MMP-2/9 enzymatic PEG deshielding → PS exposure → macrophage uptake↓TNF-α, IL-6, IL-1β; ↑IL-10——RAW264.7 uptake: 3.5× with MMP vs without; 13× vs fibroblasts[101]HTDDMicroenvironment-responsiveHA (5 kDa)-TGMS, pH-sensitive PBA linker2-DG (hydrophilic) + Dex (hydrophobic)HA (CD44)Size: ~178.6 nm; Zeta: −16.8 mV; 2-DG EE: 12.3%, DL: 1.2%; Dex EE: 72.5%pH 5.5 + MMP overexpression triggers disassembly2-DG: ↓glycolysis (11 genes incl. Hk3, Eno1); Dex: ↓NF-κB and counteracts 2-DG-induced ROS; breaks inflammation-glycolysis loopi.v.AIAProlonged Dex half-life and AUC; ~3× accumulation in inflamed vs normal joints; ↓arthritis score; ↓CD4⁺ T & M1; ↑Treg; improved synovial pathology; no hepato/renal toxicity[102]Abbreviations: CS, chondroitin sulfate; BYG, yeast β-glucan; PAMAM, polyamidoamine; MTX, methotrexate; GlcN, glucosamine; Tof, tofacitinib; FA, folate; FR, folate receptor; PTT, photothermal therapy; i.v., intravenous; CIA, collagen-induced arthritis; AIA, adjuvant-induced arthritis; FAP, fibroblast activation protein; ZF, zinc ferrite; AMF, alternating magnetic field; ERS, endoplasmic reticulum stress; DC, diclofenac prodrug; LND, lonidamine; GLUT-1, glucose transporter 1; HK-2, hexokinase 2; PVA, polyvinyl alcohol; HA, hyaluronic acid; PCL, polycaprolactone; AR, gold nanorods; CS-PEI, chitosan-polyethyleneimine; PSS, polystyrene sulfonate; HO-1, heme oxygenase-1; NIR, near-infrared; MCDs, metformin-derived carbon dots; MPDA, mesoporous polydopamine; IGU, ibudilast; PB, Prussian blue; AC, guanidine-based polymer; MCM, macrophage cell membrane; SR-B1, scavenger receptor class B type 1; DXM, dexamethasone; DSP, dexamethasone sodium phosphate; ApoE, apolipoprotein E; 2-DG, 2-deoxyglucose; Dex, dexamethasone; TGMS, triglycerol monostearate; PBA, phenylboronic acid; DL, drug loading; EE, encapsulation efficiency; PDI, polydispersity index. Comprehensive Summary of Smart Polymer Nanoparticles for Rheumatoid Arthritis Therapy Abbreviations: CS, chondroitin sulfate; BYG, yeast β-glucan; PAMAM, polyamidoamine; MTX, methotrexate; GlcN, glucosamine; Tof, tofacitinib; FA, folate; FR, folate receptor; PTT, photothermal therapy; i.v., intravenous; CIA, collagen-induced arthritis; AIA, adjuvant-induced arthritis; FAP, fibroblast activation protein; ZF, zinc ferrite; AMF, alternating magnetic field; ERS, endoplasmic reticulum stress; DC, diclofenac prodrug; LND, lonidamine; GLUT-1, glucose transporter 1; HK-2, hexokinase 2; PVA, polyvinyl alcohol; HA, hyaluronic acid; PCL, polycaprolactone; AR, gold nanorods; CS-PEI, chitosan-polyethyleneimine; PSS, polystyrene sulfonate; HO-1, heme oxygenase-1; NIR, near-infrared; MCDs, metformin-derived carbon dots; MPDA, mesoporous polydopamine; IGU, ibudilast; PB, Prussian blue; AC, guanidine-based polymer; MCM, macrophage cell membrane; SR-B1, scavenger receptor class B type 1; DXM, dexamethasone; DSP, dexamethasone sodium phosphate; ApoE, apolipoprotein E; 2-DG, 2-deoxyglucose; Dex, dexamethasone; TGMS, triglycerol monostearate; PBA, phenylboronic acid; DL, drug loading; EE, encapsulation efficiency; PDI, polydispersity index. Although we have outlined the diverse design strategies and underlying mechanisms of SPNs for RA, we should examine the gap between preclinical efficacy and clinical translational potential. This critical discussion unfolds across the following interrelated dimensions: the mechanistic basis of carrier design, comparative performance of competing platforms, biological and manufacturing barriers to translation, and the limitations of current preclinical models. The “smartness” of SPNs—operationalized through stimulus-cleavable linkers and conformation-switchable moieties—confers theoretical precision, yet each responsive modality entails inherent compromises. pH-responsive systems exploit the reliably acidic RA synovium (pH 6.0–6.8), but acidic microenvironments are not pathognomonic to RA, raising concerns about off-target release in tumors or ischemic tissues. ROS-responsive platforms capitalize on the marked oxidative burst in inflamed joints, yet ROS is a ubiquitous secondary messenger in numerous physiological processes, potentially compromising specificity. GSH-responsive disulfide chemistry benefits from dramatic intracellular/extracellular concentration gradients, but inter-patient variability in synovial GSH levels and the risk of premature systemic cleavage remain practical challenges. Enzyme-responsive systems (eg, MMP-2/9-cleavable linkers) offer arguably the highest disease specificity; nevertheless, enzyme activity fluctuates with disease stage and individual patient protease profiles, complicating predictable dosing.125 Multi-stimuli-responsive platforms have emerged as the most promising strategy to enhance release fidelity, but at the cost of increased synthetic complexity and batch-to-batch variability.126 These trade-offs underscore that “smartness” is not an absolute attribute but a design parameter that must be optimized against specificity, scalability, and regulatory feasibility. When evaluated against alternative nanomedicine platforms, SPNs occupy a distinctive but not universally superior niche. In a landmark head-to-head comparison, Quan et al116 demonstrated that polymeric micelles and HPMA copolymer prodrugs, with their sustained-release characteristics, outperformed liposomes in joint protection in AIA rats. Lipid-based carriers generally exhibit milder inflammatory responses and efficient metabolic clearance, yet they suffer from lower drug loading capacity, drug leakage during storage, and limited stability in serum. Inorganic nanoparticles (gold, iron oxide, silica) provide unique imaging and photothermal functionalities, but their clinical translation is severely hampered by long-term biopersistence, potential organ accumulation, and the absence of established biodegradation pathways—concerns that have precluded FDA approval for chronic inflammatory indications. Exosomes and biomimetic vesicles confer exceptional biocompatibility and intrinsic homing capabilities, but isolation yields are low, batch heterogeneity is high, and quality control standards remain immature. Lipid–polymer hybrid nanoparticles (LPHNs) integrate the strengths of both classes, demonstrating 27% higher cellular uptake, 30% lower cytotoxicity, and 34% greater therapeutic efficacy than single-component counterparts.127 Yet their multi-step synthesis increases manufacturing costs and complicates regulatory approval. The optimal therapeutic strategy, therefore, involves not the supremacy of a single platform but the judicious matching of carrier properties to specific clinical scenarios—acute versus chronic inflammation, monotherapy versus combination therapy, and systemic versus intra-articular administration. The translational trajectory of SPNs for RA is contingent upon resolving a quartet of interdependent challenges that span from bench synthesis to bedside administration. First, pharmacokinetic behavior is governed by the instantaneous formation of a protein corona upon intravascular entry: hydrophobic surfaces recruit opsonins (IgGs, complement, fibrinogen) that flag particles for rapid RES sequestration in the liver and spleen, whereas PEGylated or hydrophilic surfaces generate a stealth corona enriched in dysopsonins such as ApoA-I, prolonging circulation. Quantitatively, nanoparticles of ~100 nm exhibit an optimal balance, avoiding renal filtration (<6 nm) and splenic trapping (>200 nm), while intermediate elasticity (~102–103 kPa) further enhances ApoA-I adsorption and extends half-life. Across diverse compounds, intravenous nanoformulations consistently elevate AUC by a median of ~38-fold and prolong half-life up to 5-fold compared to conventional formulations.128 Yet, the EPR effect in inflamed joints remains heterogeneous, and 40–50% of intravenously administered particles are cleared by hepatic and splenic macrophages within hours, limiting joint bioavailability. Second, these pharmacokinetic realities impose stringent demands on manufacturing reproducibility. Batch-to-batch variability in particle size, polydispersity index (PDI), drug encapsulation efficiency, and surface ligand density remains a major hurdle for polymeric nanoparticles, necessitating iterative optimization of solvent removal and lyophilization steps. While microfluidic continuous-flow synthesis offers superior reproducibility and scalability compared with conventional batch methods—achieving coefficient of variation in particle size below 5% at kilogram-per-hour scales129—the transition from laboratory (μg–mg) to clinical (100 g/d) and industrial (1 kg/d) production rates requires parallelization, computational fluid dynamics (CFD) modeling, and quality-by-design (QbD) frameworks incorporating process analytical technology (PAT) and real-time release testing (RTRT).130 Sterilization without compromising particle integrity—particularly for temperature-sensitive polymeric matrices—further complicates GMP compliance. Third, long-term safety profiles present formidable obstacles. Biodegradable polymers such as PLGA degrade into glycolic and lactic acids that are metabolized via the Krebs cycle, yet acidic byproducts may inadvertently activate inflammatory cascades in the chronically inflamed joint microenvironment. More critically, repeated administration of PEGylated nanoparticles elicits anti-PEG antibodies (APAs) in a substantial fraction of patients—including those with pre-existing APAs from cosmetic or pharmaceutical exposure—triggering the accelerated blood clearance (ABC) phenomenon upon subsequent doses. APAs bind to PEGylated carriers, activate complement, and reduce circulation time and therapeutic efficacy, while also predisposing to hypersensitivity reactions ranging from urticaria to anaphylaxis. Strategies to mitigate APA formation include fast-shedding PEG-lipids, terminal group substitution (eg, hydroxyl-PEG), and alternative stealth polymers such as poly(2-oxazoline), polyglycerol, and zwitterionic materials that evade immunogenicity entirely.131 Beyond PEG immunogenicity, cationic polymer residues (eg, PEI, chitosan derivatives) can activate complement and induce cytotoxicity, whereas non-degradable inorganic cores accumulate in RES organs and raise chronic toxicity concerns.132 Fourth, addressing these multifaceted challenges necessitates a paradigm shift toward intelligent, data-driven design. Artificial intelligence (AI) and machine learning (ML) algorithms are revolutionizing nanomedicine development by enabling high-throughput polymer screening, predicting structure–activity relationships, and optimizing drug release kinetics based on large experimental datasets. Generative adversarial networks (GANs) and reinforcement learning can design polymeric scaffolds and nanoparticle surface chemistries that maximize endothelial uptake while minimizing immune clearance. ML-driven analysis of multi-omics datasets further offers a transformative framework for precision-engineered therapies customized to patient-specific immunogenetic profiles, potentially stratifying patients based on baseline anti-PEG antibody levels or synovial microenvironment signatures. Integration of automated microfluidic platforms with AI-driven process optimization may substantially enhance production consistency and quality control, bridging the gap between preclinical promise and clinical reality.133 Ultimately, the convergence of mechanistic pharmacokinetic understanding, GMP-compliant scalable manufacturing, proactive immunogenicity mitigation, and AI-guided personalized design will determine whether SPNs transition from promising preclinical constructs to standard-of-care therapeutics for rheumatoid arthritis. It is worth noting that the therapeutic mechanisms reviewed herein predominantly derive from collagen-induced arthritis (CIA) and adjuvant-induced arthritis (AIA) models, yet these experimental systems exhibit fundamental disparities with human RA that constrain their predictive validity. CIA, the most widely employed model, requires both T-cell and B-cell responses to autologous type II collagen and reproduces synovitis, pannus formation, and progressive bone erosion, making it the benchmark for preclinical efficacy testing. However, CIA develops rapidly over weeks rather than the chronic, relapsing-remitting course characteristic of human RA, and critically, CIA mice and rats lack anti-citrullinated protein antibodies (ACPAs)—the serological hallmark and key pathogenic driver in approximately 70% of human RA patients.134 This absence of ACPA-mediated immunity fundamentally alters the immunological landscape, rendering CIA inadequate for evaluating therapies targeting citrullination pathways or ACPA-producing B-cell subsets. AIA, induced by complete Freund’s adjuvant, is even more problematic: it is self-limiting, typically resolving within a few weeks, and is now recognized as a more appropriate model for reactive arthritis than for RA due to divergent histological and immunological features. The acute, monophasic inflammation of AIA fails to capture the sustained synovial hyperplasia, tertiary lymphoid neogenesis, and adaptive immune dysregulation that define human disease chronology.135 Furthermore, both CIA and AIA rely on artificial immunization protocols that bypass the genetic and environmental risk factors (eg, HLA-DRB1 shared epitope, smoking, microbiome) implicated in human RA pathogenesis, and neither model adequately recapitulates the systemic comorbidity burden—cardiovascular, metabolic, and psychological—that profoundly impacts patient outcomes. Emerging alternatives such as the K/BxN serum-transfer model (autoantibody-driven), pristane-induced arthritis (PIA, T-cell-mediated), and humanized mouse models engrafted with patient-derived immune cells offer incremental improvements in face validity, yet each introduces its own limitations: K/BxN overemphasizes humoral mechanisms at the expense of cellular immunity, PIA exhibits limited antibody involvement, and humanized models remain technically demanding, expensive, and incompletely engrafted.135 Collectively, these translational gaps contribute to the well-documented attrition of nanomedicine candidates from preclinical promise to clinical failure. Future SPN development for RA must therefore incorporate multi-model validation—spanning at least two distinct species and pathogenic mechanisms—alongside human ex vivo synovial tissue assays and organ-on-chip platforms that preserve the three-dimensional architecture and cellular heterogeneity of the rheumatoid joint, thereby bridging the chasm between rodent efficacy and human therapeutic benefit. Conclusion and Outlook Despite impressive preclinical efficacy, SPNs face substantial translational barriers. CIA/AIA models lack ACPAs and fail to recapitulate human disease chronology. The EPR effect in human joints is weaker and more heterogeneous than in rodents, with 40–50% of intravenously administered nanoparticles cleared by RES organs within hours. Manufacturing scale-up remains constrained by batch variability and sterilization challenges.128,130 Safety concerns include PLGA degradation byproducts, anti-PEG antibody-mediated ABC phenomenon, and uncertain long-term fate of non-degradable components. While SPNs demonstrate targeted accumulation, stimulus-responsive release, and macrophage repolarization in rodents, clinical translation remains nascent. Clinically, however, the field remains in early phases: while liposomal prednisolone and PEGylated biologics have achieved regulatory approval for RA, these are not stimulus-responsive systems in the sense reviewed here. No Phase III data for intelligent polymeric nanocarriers in RA yet exist, and the few SPN platforms entering early-stage trials remain preliminary. Near-term (2025–2030): validate in large-animal models and human synovial organ-on-chip platforms;136 deploy AI-driven formulation optimization. Mid-term (2030–2035): Phase I/II trials with imaging-guided dosing and multi-omics patient stratification. Long-term (2035+): personalized adaptive nanomedicine integrating microenvironment profiling, immunogenicity screening, and real-time therapeutic monitoring.137 In summary, SPNs represent a paradigm shift from empirical dosing to intelligent, microenvironment-adaptive therapy for RA. Yet realizing this potential demands that the field move beyond demonstrative efficacy in rodent models toward mechanistically grounded, safety-focused, and clinically validated research. Only through candid acknowledgment of current limitations and systematic execution of this translational roadmap can SPNs transit from promising laboratory constructs to transformative clinical therapeutics for rheumatoid arthritis.